PrECOG Protocol Number: PrE0 404 
Date: 8/21/2020  
 
 
 
PrECOG Protocol Number: PrE0404 
A Phase I/II Study of Ixazomib and Ibrutinib in 
Relapsed/Refractory Mantle Cell Lymphoma  
 
 
 
 
 
 NCT#:  [STUDY_ID_REMOVED]  
IND #:  
 Exempt  
Protocol Version Number: 
 3.0 
Version Date:  
 8/21/2020  
 

PrECOG Protocol Number: PrE0404 
Confidential  
Date: 8/21/2020 
 
 
 
PrECOG Protocol Number: PrE0404 
A Phase I/II Study of Ixazomib and Ibrutinib in 
Relapsed/Refractory Mantle Cell Lymphoma  
STUDY CHAIR:  Jonathon B. Cohen, MD  
STUDY CO -CHAIRS:  
 
ECOG -ACRIN LYMPHOMA COMMITTEE CHAIR:   
STATISTICIAN:   
PRECOG STUDY SITE CO NTACT:  Carolyn Andrews, RN  
MEDICAL MONITOR:   
(Internal Use Only) [COMPANY_005]  US Ref. ID Number : X16077  
 
 
 
 
 
   
IND #:  
 Exempt  
Version Number: 
 3.0 
Version Date:  
 8/21/2020  
  
Release/Revision History  
Version 1.0 : 9/20/2017  Released to Sites  
Version 2.0: 12/17 /2019 Released to Sites  
Version 3.0: 8/ 21/2020  Released to Sites  
 
This protocol contains information that is confidential and proprietary  

PrECOG Protocol Number: PrE0404 
Confidential  
Date: 8/21/[ADDRESS_12091] of Abbreviations  ....................................................................................................................................8  
1. Introduction- Background and Rationale  ........................................................................................ 12 
1.1 Mantle Cell Lymphoma – Disease Overview  ............................................................................. 12 
1.2 Background/Rationale  ................................................................................................................ 12  
1.3 Ixazomib (MLN9708)  .................................................................................................................. 14  
1.3.1  Preclinical Experience  ................................................................................................. 14 
1.3.2  Clinical Experience  ...................................................................................................... 14 
1.3.3  Pharmacokinetics and Drug Metabolism  ..................................................................... 15 
1.3.4  Clinical Trial Experience Using the Oral Formulation of Ixazomib .............................. 15 
1.3.5  Overview of the Oral Formulation of Ixazomib ............................................................ 16 
1.3.6  Clinical Trial Experience with Ixazomib in NHL28 ........................................................ 16 
1.4 Ibrutinib  ...................................................................................................................................... 17 
1.4.1  Toxicity32 ...................................................................................................................... 17 
1.5 Summary of Rationale for Proposed Study  ............................................................................... 18 
1.5.1  Rationale  ...................................................................................................................... 18 
1.5.2  Rationale for the Study Design and  Treatment Plan  ................................................... 19 
2. Study Objectives  ................................................................................................................................ 20 
2.1 Primary Objective  ....................................................................................................................... 20 
2.1.1  Phase I  ......................................................................................................................... 20 
2.1.2  Phase II  ........................................................................................................................ 20 
2.2 Secondary Objectives  ................................................................................................................ 20  
2.2.1  Phase I  ......................................................................................................................... 20 
2.2.2  Phase II  ........................................................................................................................ 20 
2.3 Exploratory Objectives  ............................................................................................................... 20  
3. Selection of Patients  .......................................................................................................................... 21 
4. Registration Procedures  .................................................................................................................... 25 
4.1 Ethics  ......................................................................................................................................... 25 
4.2 Regulatory Requirements  .......................................................................................................... 25  
4.3 Phase I and II Patient Registration  ............................................................................................ 25 
4.4 Research Bone Marrow, Tissue and Blood Samples  ................................................................ 26 
5. Study Design  ...................................................................................................................................... 27 
5.1 Phase I  ....................................................................................................................................... 27 
5.2 Phase II  ...................................................................................................................................... 27  
6. Treatment Plan  ................................................................................................................................... 29 
6.1 Overview  .................................................................................................................................... 29 
6.1.1  Ixazomi b Administration  .............................................................................................. 29 
6.1.2  Ibrutinib Administration  ................................................................................................ 29 
6.2 Phase I Treatment Adm inistration  ............................................................................................. 29 
6.2.1  DLT Assessment  ......................................................................................................... 30 
6.3 Phase II Treatment Administration  ............................................................................................ 31 
6.4 Criteria to Begin a New Cycle of Therapy  .................................................................................. 32 
6.5 Dose Delays & Modifications  ..................................................................................................... 32 
6.5.1  Dose Reductions/Modifications for Ixazomib and Ibrutinib  ......................................... 33 
PrECOG Protocol Number: PrE0404 
Confidential  
Date: 8/21/2020  
 
3 6.5.2  Additional Dose Reductions/Modifications for Ibrutinib  ............................................... 36 
6.6 Concurrent Therapi[INVESTIGATOR_014]  ................................................................................................................ 37  
6.6.1  Required and/or Permitted .......................................................................................... 37 
6.6.2  Not Permitted ............................................................................................................... 37  
7. Study Duration and Discontinuation of Therapy  ............................................................................ 39 
7.1 Study Duration  ........................................................................................................................... 39 
7.2 Duration of Follow -Up ................................................................................................................ 39  
7.3 Criteria for Removal from  Study Treatment  ............................................................................... 39 
8. Adverse Event Reporting  .................................................................................................................. 41  
8.1 Collection of Safety Information  ................................................................................................. 41 
8.2 Handling of Serious Adverse Events (SAEs)  ............................................................................. [ADDRESS_12092]  ....................................................................................................................... 45 
9.1 Scheduled Restaging Studies  .................................................................................................... 45 
9.2 Complete Response (CR ) .......................................................................................................... 45  
9.3 Partial Response (PR)  ............................................................................................................... 45  
9.4 No Response/Stable Disease (SD)  ........................................................................................... 46 
9.5 Progressive Disease (PD) .......................................................................................................... 46  
9.6 Criteria for PET/CT Reporting  .................................................................................................... 47 
10. Study Parameters  ............................................................................................................................... 48 
11. Drug Formulation and Procurement  ................................................................................................ 52 
11.1  Ixazomib36 .................................................................................................................................. 52 
11.1.1  Other Names  ............................................................................................................... 52  
11.1.2  Classification ................................................................................................................ 52  
11.1.3  Storage and Stability  ................................................................................................... 52 
11.1.4  Dose Specifics  ............................................................................................................. 52  
11.1.5  Route of Administration  ............................................................................................... 53 
11.1.6  Drug Interactions  ......................................................................................................... 53 
11.1.7  Agent Availability  ......................................................................................................... 53 
11.1.8  Agent Ordering  ............................................................................................................ 53  
11.1.9  Agent Accountability  .................................................................................................... 53 
11.1.10  Side Effects .................................................................................................................. 54  
11.2  Ibrutinib37 .................................................................................................................................... 56 
11.2.1  Other Names  ............................................................................................................... 56  
11.2.2  Classification ................................................................................................................ 56  
11.2.3  Mode of Action  ............................................................................................................. 56  
11.2.4  Storage and Stability  ................................................................................................... 56 
11.2.5  Dose Specifics  ............................................................................................................. 56  
11.2.6  Route of Administration  ............................................................................................... 56 
11.2.7  Drug Interactions  ......................................................................................................... 56 
11.2.8  Availability  .................................................................................................................... 57 
PrECOG Protocol Number: PrE0404 
Confidential  
Date: 8/21/2020  
 
4 11.2.9  Side Effects .................................................................................................................. 57  
11.2.10  Nursing/Patient Implications  ........................................................................................ 58 
12. Statistical Con siderations  ................................................................................................................. 59  
12.1  Study Design & Sample Size Considerations  ............................................................................ [ADDRESS_12093] (IRB)  ................................................................................................ 67 
14.3  Informed Consent Procedures  ................................................................................................... 67 
14.4  Safety Communicati on ............................................................................................................... 68  
14.5  Monitoring  .................................................................................................................................. 68 
14.6  Study Records  ........................................................................................................................... 68 
14.7  Electronic Case Report Form (eCRF) Information  .................................................................... 69 
14.8  Records Retention  ..................................................................................................................... 69 
15. References  .......................................................................................................................................... 70 
Appendix I  ECOG Performance Status ....................................................................................... 73 
Appendix II:  NYHA Classification  .................................................................................................. 74 
Appendix III:  Ixazomib Medication Diary ....................................................................................... 75 
Appendix IV:  Ibrutinib Medication Diary  ........................................................................................ 76 
Appendix V:  Investigator’s Statement  ........................................................................................... 78 
 
  
PrECOG Protocol Number: PrE0404 
Confidential  
Date: 8/21/[ADDRESS_12094] 
Philadelphia, PA [ZIP_CODE]  
Phone: [PHONE_223]  
Email: [EMAIL_219]  
[ADDRESS_12095]  
Wayne , PA 19 087 
During normal business hours  
(8:30 am -5:[ADDRESS_12096]):  
Phone: 610- 354-0404  
After normal business hours:  
Phone: 484- 574-2367  
Email:  
SAE Email : [EMAIL_220]  
 

PrECOG Protocol Number: PrE0404 
Confidential  
Date: 8/21/2020  
 
6 Brief Protocol Synopsis 
See Protocol Document Sections for complete details  
Study Schema  
Phase I  
 
 
  
 
    
 
Phas e I: Treatment should begin within 10 working days of registration . 
Phase I: Dose Limiting Toxicity (DLT)  will be assessed through Cycle 1.  Refer to Section 6.2.1 for details.  
Phase I Accrual:  Maximum of 1 2 patients.  
Three patients were enrolled to Dose Level 1 with no DLTs during the 28 day assessment period. Nine 
patients were enroll ed to Dose Level 2,  five of the nine patients completed the 28 day assessment period 
with no DLTs, and one patient experienced a Grade 3 lung infection that was considered a DLT. Three of 
the nine patients were not evaluable for DLT and were replaced. One patient was inadvertently  given 
neulasta prior to receiving Cycle 2, Day 1 therapy ; another patient unintentionally took Day 15 ixazomib on 
Day 9 ; and one patient forgot to take ibrutinib the last 8 days of Cycle 1 unrelated to any toxicities . Phase I 
was completed November 25 , 2019.  Dose Level 2 is the recommended Phase 2 dose.  
  Dose Level  Ixazomib  
Days 1, 8, 15 of 
a 28 Day Cycle Ibrutinib  
Days 1 -28 of a 
28 Day Cycle  
-1 3 mg  420 mg 
1 
Starting D ose 3 mg  560 mg 
2 4 mg 560 mg Open to Ibrutinib-
Naïve and Selected 
Pretreated Patients  
PrECOG Protocol Number: PrE0404 
Confidential  
Date: 8/21/2020  
 
7 Phase II  
 
 
   
 
 
 
RP2D:  Recommended Phase 2 D ose 
BTK:  Bruton’s Tyrosine Kinase  
Phase II:  Treatment should begin within 10 working days of registration. 
Phase II Accrual Goal:  Maximum of [ADDRESS_12097] 7 , 2020:  
Cohort A will continue to enroll patients (see below) and enrollment to Cohort B  
is closed.  
Cohort A : 31 eligible, treated patients will be accrued (see below ). 
Cohort B : [ADDRESS_12098] 7 , 2020:  Phase II opened December 17, 2019 with  Cohort A: BTK- naïve or Cohort B: BTK -
pretreated.  
Enrollment to Cohort A: BTK -naïve will continue.  We plan to reach our original accrual goal of 36 BTK -
naïve subjects treated at the established Dose Level 2 for 31 eligible, treated patients. The Phase I BTK -
naïve patients treated at Dose Level 2 will be included in the 36 patient total. Seventeen addit ional BTK-
naïve patients will be enrolled to complete this cohort.  
Enrollment to Cohort B: BTK -pretreated  will close.  To date, only two patients have enrolled in Cohort  B. Ixazomib  
Days 1, 8, 15 of a 
28 Day Cycle  Ibrutinib  
Days 1 -28 of a 
28 Day Cycle  
4 mg 560 mg  Dosed at RP2D  
Cohort A: BTK-Naive  
Cohort B: BTK-Pretreated : 
Closed to Enrollment 8/ 7/2020  
PrECOG Protocol Number: PrE0404 
Confidential  
Date: 8/21/[ADDRESS_12099] Cancer Resistance Protein  
BM Bone M arrow  
BSA Body Surface A rea 
BTK Bruton’s Tyrosine Kinase  
BUN  Blood Urea N itrogen  
CBC  Complete Blood C ount 
CFR Code of Federal Regulations  
CI Confidence Interval  
Cmax Maximum (peak) C oncentration  
CNS  Central Nervous S ystem  
CR Complete R esponse  
CT Computed T omography  
CTCAE  Common Terminology Criteria for Adverse Events  
CYP Cytochrome P 450 
DDI Drug- Drug Interaction  
DLT Dose- Limiting T oxicity  
DRESS  Drug Reaction with Eosinophilia and Systemic Symptoms 
ECG  Electrocardiogram  
ECOG  Eastern Cooperative Oncology Group  
eCRF  Electronic Case Report F orm 
PrECOG Protocol Number: PrE0404 
Confidential  
Date: 8/21/[ADDRESS_12100]  
HIV Human I mmunodefici ency V irus 
IB Investigator’s Brochure  
ICF Informed Consent F orm 
ICH International Conference on Harmonisation  
IHC ImmunoHistoChemistry  
IND Investigational New Drug  
INR International Normalized Ratio  
IRB Institutional R eview Board 
IV Intravenous ; Intravenously  
KPS Karnofsky Performance Status  
LDH Lactate D ehydrogenase  
LenDex  Lenalidomide plus D examethasone  
MCL  Mantle Cell Lymphoma  
MedDRA  Medical Dictionary for Regulatory Activities  
mL Milliliter  
MM Multiple M yeloma  
MRI Magnetic Resonance I maging  
MRP2  Multidrug Resistance Associated Protein 2  
MTD  Maximum Tolerated D ose 
N Number  
NCDB  National Cancer Data Base  
NCI National Cancer Institute  
PrECOG Protocol Number: PrE0404 
Confidential  
Date: 8/21/2020  
 
10 Abbreviation Term  
NCI CTCAE  National Cancer Institute Common Terminology Criteria for Adverse 
Events  
NDMM  Newly Diagnosed Multiple M yeloma  
NEC  Not Elsewhere Classified  
NHL Non- Hodgkin’s Lymphoma 
NIH National Institutes of Health  
ORR Overall Response Rate  
OS Overall Survival  
PBMC  Peripheral Blood Mononuclear C ell 
PCR  Polymerase Chain R eaction 
PD Progressive Disease (disease progression)  
PET Positron Emission Tomography  
PFS Progression Free Survival  
Pgp P-Glycoprotein  
PK Pharmacokinetic(s)  
PML Progressive Multifocal L eukoencephalopathy  
PO per os ; By M outh (orally)  
PR Partial R esponse  
PT Partial Thromboplastin Ti me 
RevDex  Revlimid plus Dexamethasone  
RP2D  Recommended Phase 2 D ose 
RRAL  Relapsed and/or R efractory  Systemic Light Chain (AL) A myloidosis  
RRMM  Relapsed and/or Refractory Multiple M yeloma 
SAE Serious Adverse E vent 
SD Stable D isease  
SPD Sum of the Product of the D iameters  
SRM  Study Reference Manual  
TEAE  Treatment -Emergent Adverse Event  
TEN Toxic Epi[INVESTIGATOR_12651] -Dose Time to Reach Maximum (peak) C oncentration  
TNFα  Tumor Necrosis Factor -alpha  
TTP Thrombotic Thrombocytopenic Purpura  
ULN Upper Limit of the Normal R ange  
PrECOG Protocol Number: PrE0404 
Confidential  
Date: 8/21/2020  
 
11 Abbreviation Term  
US [LOCATION_002]  
WBC  White Blood C ell 
 
PrECOG Protocol Number: PrE0404 
Confidential  
Date: 8/21/2020  
 
12 1. Introduction - Background and Rationale  
1.1 Mantle Cell Lymphoma – Disease Overview  
Mantle cell lymphoma (MCL)  is a rare subtype of non- Hodgkin lymphoma that is considered 
incurable with conventional therapy. The disease is identified through a characteristic 
chromosomal translocation [i.e., t(11;14)]  which results in overexpression of cyclin D 1. 
While patients who receive aggressive induction therapy followed by [CONTACT_12676] (ASCT) can have a prolonged overall 
survival  (OS) , ASCT is not considered c urative 
and the OS  for all diagnosed patients has not 
changed over the past several years (Figure 1). Current approaches to induction therapy for fit patients includes aggressive inpatient chemotherapy regimens followed by [CONTACT_12677], 
which can result in responses of 5- 8 years in 
many patients and prolonged OS.
1-3 
For relapsed patients, ibrutinib, lenalidomide, 
and bortezomib are all Food and Drug 
Administration (FDA) -approved options, 
although these do not represent curative approaches.
4-6 While ibrutinib has a high overall 
response rate (ORR)  of 67%  in heavily pre-
treated patients , the 2- year progression- free 
survival (PFS) is only 31%.[ADDRESS_12101] a very poor prognosis, 
with an OS  of 8 months .8 Novel approaches are 
required to improve outcomes for patients with 
relapsed/refractory MCL, and to improve the remission duration for patients completing their initial therapy . 
1.2 Background/Rationale  
Proteasome inhibition remains an integral approach to the management of MCL. The sing le 
agent ORR  of bortezomib in the relapsed/refractory setting is 33%, including 8% complete 
response (CR) rate, and the median duration of  response is roughly [ADDRESS_12102] -transplant maintenance setting, where the 5-year PFS  for patients treated on 
CALGB [ZIP_CODE] was 73%, compared to 52% for patients treated on the prior trial (CALGB 
[ZIP_CODE]) where bortezomib was omitted  (p=0.0006) .3,[ADDRESS_12103] notably 
peripheral neuropathy, which occurred at grade 3 or higher in 13% of patients enrolled on 
the single agent study.6 
While bortezomib and proteasome inhibition represents an effective therapy for a subset of 
patients, the novel Bruton’s tyrosine kinase (BTK) inhibitor, ibrutinib has an even higher ORR of 68% and appears to be well -tolerated.
[ADDRESS_12104] evaluated 
drugs with targets close to BTK in the B-Cell Receptor ( BCR ) pathway (proximal) as well as 
drugs with targets far from BTK or not clearly in the BCR pathway (distal) (Figure 2).
12 
Figure 1. Overall survival (OS) of newly diagnosed 
patients with mantle cell lymphoma in the [LOCATION_002], based on time of diagnosis. Source: National Cancer Data Base (NCDB).  
 
PrECOG Protocol Number: PrE0404 
Confidential  
Date: 8/21/[ADDRESS_12105] cytotoxicity (Figure 3 a) and apoptosis induction (Figure 3b) . Proteasome 
inhibitor and ibrutinib combination also had an improved survival in a mouse- human 
xenograft model (Figure 4).
12 
 
 
 
 
The orally available proteasome inhibitor, ixazomib, is currently under investigation in 
lymphoma and multiple myeloma. Ixazomib  citrate (MLN9708)  is immediately converted to 
its active metabolite, Ixazomib ( MLN2238) , upon ingestion, resulting in inhibition of TNFα -
induced activation of NFκB.  In WSU -DLCL2 tumor -bearing mice, MLN2238 generated a 
stronger anti -tumor activity and greater apoptotic response (measured by [CONTACT_12678]-3) compared to bortezomib. In a murine disseminated lymphoma model (NOD -
SCID mice inoculated with OCI -Ly7-Luc cells) anti -tumor activity of MLN2238 was better 
Figure 2.  Hierarchical 
clustering of % synergy 
by [CONTACT_12679].  
Figure 3.  % cytotoxicity of 
ibrutinib and carfilzomib in MCL 
cell lines and patient samples.  Figure 4.  OS in xenograft model.  
PrECOG Protocol Number: PrE0404 
Confidential  
Date: 8/21/2020  
 
14 than bortezomib, where median OS was 54 days for mice exposed to MLN2238 compared 
to 33 days for vehicle controls (p=0.05). Median OS was not significantly different for 
bortezomib- treated mice compared to those exposed to vehicle controls (p>0.99).13 In a 
subsequent experiment evaluating in vivo activity of ixazomib in OCI -Ly10 tumor -bearing 
SCID mice, the anti -tumor activity (treated vs. control; T/C) of ixazomib was improved (T/C 
= 0.37) compared to bortezomib (T/C = 0.68) in this model based on a human cell line of activated-B- cell like  diffuse large B -cell lymphoma.  In vivo anti -tumor activity was also 
demonstrated in PHTX22L tumor -bearing NOD -SCID mice (T/C for ixazomib 0.14, p<0.01), 
while bortezomib did not demonstrate significant anti -tumor activity.
14 
Based on these pre- clinical findings in murine models, ixazomib has been evaluated in early 
phase clinical trials. In a phase I study of the IV formulation of ixazomib in 
relapsed/refractory Non- Hodgkin’s Lymphoma ( NHL), 30 patients were treated at 8 dose 
levels, including 10 at the maximum tolerated dose (MTD) of 2.34 mg/m2 on days 1, 8, and 
15. Five of twenty -six patients responded, with durat ions ranging from 6- [ADDRESS_12106] common adverse 
events were neutropenia, gastrointestinal  (GI) toxicity, and acute renal failure secondary to 
GI toxicit y.15 Ixazomib has also been evaluated alone and combined with other agents in 
multiple myeloma, where the oral formulation has a MTD of 2.97 mg/m2 on days 1, 8, and 
15 of 28 day cycles. Notably, there were no instances of grade 3- 4 peripheral neuropathy 
in a single agent phase I study of weekly ixazomib.16 An additional phase I study of twice-
weekly ixazomib in multiple myeloma found an MTD of 2.0  mg/m2 on days 1, 4, 8, and 11 
of a 21 day cycle, with only 11% of patients experiencing peripheral neuropathy and no 
cases of grade 3- [ADDRESS_12107] -transplant maintenance 
in multiple myeloma ([STUDY_ID_REMOVED]) and combination studies are planned in lymphoma.  
1.3 Ixazomib (MLN9708)  
1.3.1  Preclinical Experience  
Please refer to the current Ixazomib Investigator’s Brochure (IB) . 
1.3.2  Clinical Experience  
Ixazomib has been evalua ted as an oral single agent in phase 1, phase 1/2 and 
phase 2 studies in multiple myeloma (MM), systemic light -chain amyloidosis  (AL),  
solid tumors , and lymphoma. In addition, Phase I studies are completed  in patients 
with renal or hepatic impairment  to evaluate the effect on food on ixazomib 
pharmacokinetics ( PK), to evaluate drug- drug interactions ( DDI’s ), and to 
characterize ixazomib absorption,  distribution,  metabolism,  and excretion (ADME)  
have been conducted. Phase  3 trials in RRMM,  newly  diagnosed multiple  
myeloma  (NDMM), and relapsed or refractory  systemic light -chain amyloidosis  
(RRAL  amyloidosis)  are underway.  As of [ADDRESS_12108] 1 dose of either the IV or oral  ixazomib  
formulations  across the clinical development program;  in addition,  [ADDRESS_12109] enrolled in 7 phase  3 clinical  trials:  
• Double- blind, placebo -controlled Global Study  C16010 and Study  C16010  
China continuation study  (CCS) of ixazomib  versus  placebo in combination 
with LenDex  in patients  with RRMM  
• Double- blind, placebo -controlled Study  C16014 and Study C16014 South 
Korea extension study (KES)  of ixazomib  versus  placebo in combination  with 
LenDex  in patients  with NDMM  
 
PrECOG Protocol Number: PrE0404 
Confidential  
Date: 8/21/2020  
 
15 • Double- blind, placebo -controlled Study  C16019 of ixazomib versus placebo as 
maintenance in patients  with NDMM  
• Open- label Study  C16011 of  ixazomib and dexamethasone versus  physician’s 
choice of a dexamethasone -containing regimen in patients  with AL amyloidosis  
Regardless, of the route of administration,  in the twice -weekly  dosing schedule  
ixazomib  is given on Days 1, 4, 8, and 11 of a 21-day cycle,  and in the weekly 
dosing schedule  ixazomib  is given  on Days  1, 8, and 15 of a 28-day cycle  
(approved schedule) . 
In 2015, FDA approval was received for ixazomib (NINLARO®) in combination with 
lenalidomide and dexamethasone for the treatment of patients with multiple 
myeloma who have received at least one prior therapy.  
Adverse events (AEs) observed to date (as of 27 March 2017) are generally 
reversible,  are manageable with standard medical  interventions, and are dose  
dependent.  The type of AEs are generally  consistent across the patient 
populations  treated to date, though some AEs may  be more common  either due to 
the patient population or the regimen being studied (e.g., thrombocytopenia is more 
common  with weekly  single -agent  ixazomib  in RRMM  than in RRAL  amyloidosis;  
thrombocytopenia is more common with weekly  ixazomib  + LenDex  in RRMM than 
ixazomib + LenDex in NDMM; myelosuppression is more common overall when ixazomib is combined with MelPred; nausea is common  across studies; and 
diarrhea is more  common  with weekly  ixazomib  + LenDex than with single- agent 
ixazomib).  Such diffe rences may illustrate effects of the disease  or prior therapy  on 
the body  (e.g., on the bone marrow) as well as the side effect profile of the agents 
in a combination regimen.  
The most commonly  observed  (≥ 30% incidence) treatment -emergent AEs 
(TEAEs) from  pooled data across clinical studies with oral ixazomib  include 
nausea and diarrhea (43% each),  fatigue  (39%), rash (all terms;  36%), and 
vomiting  (33%). The frequency of rash is noted in an aggregate because it is  
characterized in different ways; however,  it is less common  when considering 
individual  preferred terms.  
Additional detailed information regarding the clinical experience of ixazomib  may be 
found in the IB, including information on the IV formulation.  
1.3.[ADDRESS_12110] time to 
maximum observed plasma concentration ( T
max) of approximately [ADDRESS_12111] dose. 
The plasma exposure (AUC)  of ixazomib increases in a dose- proportional manner 
over a dose range of 0.2 to 10.6 mg based on population PK analysis.19 The 
absolute oral bioavailability (F) of ixazomib is estimated to be 58% based on population PK analysis.  A high- fat meal reduced ixazomib C
max by 69%  and 
AUC 0-216 by 28% . This indicates that  a high- fat meal decreases both the rate and 
extent of absorption of ixazomib. Therefore, ixazomib should be taken on an empty stomach (at least 2 hours after food or 1 hour before food). 
Detailed information regarding pharmacokinetics and drug metabolism is available 
in t
he IB.  
1.3.[ADDRESS_12112] been treated with different doses of ixazomib either as a single-
agent treatment  or in combination with currently clinically available treatments. 
PrECOG Protocol Number: PrE0404 
Confidential  
Date: 8/21/[ADDRESS_12113] medical intervention, or, as needed, dose modification or discontinuation.  
In the 4 ongoing studies (C16003, C16004, C16007, and C16009) investigating single- agent oral ixazomib in patients with differing malignancies (multiple 
myeloma, AL amyloidosis, non- hematologic cancers, and lymphoma), a total of [ADDRESS_12114] frequent (at least 10%) AEs occurring in the pooled safety population from single- agent oral ixazomib Studies (C16003, C16004, C16007, and C16009)  is 
provided in the latest IB.  
The clinical experience with ixazomib  also shows early signs of antitumor activity 
as evidenced by [CONTACT_2669] a 50% reduction in disease burden in some patients and 
prolonged disease stabilization in others across all ongoing trials. The antitumor 
activity has been seen with single- agent ixazom ib, when combined with established 
therapi[INVESTIGATOR_014], and across the malignancies studied (advanced solid tumors
20, non-
Hodgkin’ s disease, Hodgkin’s disease21, RRMM22,23, relapsed or refractory 
systemic light chain amyloidosis [RRAL]24, and NDMM25,26,27) to date.  
Though additional data are needed to characterize the clinical benefit of this drug, the emerging data supports the ongoing development of ixazomib . 
1.3.6  Clinical Trial Experience with Ixazomib in NHL
28 
Ixazomib was evaluated in IV form in a dose- escalati on study for nearly all 
lymphoma subtypes. Patients received an IV bolus on days 1, 8, and 15 of a 28-day cycle for up to 12 months. Thirty patients received therapy, including 2 patients 
with MCL. The majority of patients had follicular lymphoma (n=11), diffuse large b -
cell lymphoma (n=5) and peripheral T -cell lymphoma (n=4). Four DLT’s were 
identified, including neutropenia (n=2), acute renal failure (n=1) and one patient with 
fatigue, nausea, vomiting, and diarrhea. Ultimately, 2.34 mg/m
2 was determined to 
be the MTD using the IV formulation. Additional grade ≥3 drug- related toxicities 
included neutropenia (n=6), thrombocytopenia (n=4), diarrhea (n=3), and 
dehydration, lymphopenia, renal failure, and skin disorders (n=2).  
Five of 26 evaluable patients experienced a complete or partial response, including 
3 with follicular lymphoma and 1 patient with peripheral T -cell lymphoma. Six 
additional patients (including a MCL patient) had stable disease lasting a median of 3.6 months.  
A study of oral ixazomib in relapsed/refractory follicular lymphoma has recently 
been completed ([STUDY_ID_REMOVED]).  
 
PrECOG Protocol Number: PrE0404 
Confidential  
Date: 8/21/2020  
 
17 1.4 Ibrutinib  
The Bruton’s tyrosine kinase inhibitor (BTK) ibrutinib (Imbruvica®) was FDA approved for 
the management of previously treated MCL in 2013 based on the results of a single agent 
phase II study.  The FDA -approved dose for MCL is 560  mg once dai ly. In the pi[INVESTIGATOR_12652] , which incorporated bortezomib- pretreated and -naïve pat ients, the ORR  was 67%, 
a significant improvement over previously reported single- agent response rates for 
bortezomib and lenalidomide.4-6 In addition to this response rate, the median duration of 
response is 17.5 months. Additional therapy options, including combination therapy and 
novel treatments are currently under investigation.  In addition to single agent studies, 
ibrutinib has been evaluated in combination in MCL. In a phase Ib/II study of ibrutinib, 
rituximab, and bendamustine, the ORR  for the patients with MCL (n=17) was 94%.29 When 
combined with rituximab alone in relapsed/refractory MCL, the ORR  (n=45) is 87%, while  
100% of patients with a Ki67 <50% responded.[ADDRESS_12115] notably, the C481S mutation of BTK.31 In a recent update of long-
term follow -up for the phase II study, the 2-year PFS  was only 31%, indicating that a 
substantial portion of treated patients will progress within the first [ADDRESS_12116] be monitored and addressed for all patients who are receiving prolonged therapy.  
[IP_ADDRESS]  Hemorrhage 
Fatal bleeding events have occ urred in patients treated with ibrutinib . 
Grade 3 or higher bleeding events (subdural hematoma, gastrointestinal bleeding, hematuria and post procedural hemorrhage) have occurred in up to 6% of patients. Bleeding events of any grade, including bruising and  petechiae, occurred in approximately half of 
patients treated with ibrutinib. The mechanism for the bleeding events 
is not well understood.  Ibrutinib may increase the risk of hemorrhage in 
patients receiving antiplatelet or anticoagulant therapi[INVESTIGATOR_014].  Consider the 
benefit -risk of withholding ibrutinib  for at least [ADDRESS_12117] -
surgery depending upon the type of surgery and the risk of bleeding. 
[IP_ADDRESS]  Infections  
Fatal and non- fatal infections have occurred with ibrutinib therapy. 
Grade 3 or greater infections occurred in 14% to 26% of patients. 
Cases of progressive multifocal leukoencephalopathy (PML) have 
occurred in patients treated with ibrutinib . Monitor patients for fever and 
infections and evaluate promptly.  
[IP_ADDRESS]  Cytopenias  
Treatment -emergent Grade 3 or 4 cytopenias including neutropenia 
(range, 19 to 29%), thrombocytopenia (range, 5 to 17%), and anemia 
(range, 0 to 9%) occurred in patients treated with ibrutinib . 
 
PrECOG Protocol Number: PrE0404 
Confidential  
Date: 8/21/2020  
 
18 [IP_ADDRESS]  Atrial Fibrillation  
Atrial fibrillation and atrial flutter (range, 6 to 9%) have occ urred in 
patients treated with ibrutinib, particularly in patients with cardiac risk 
factors, acute infections, and a previous history of atrial fibrillation. Periodically monitor patients clinically for atrial f ibrillation. Patients who 
develop arrhythmic symptoms (e.g., palpi[INVESTIGATOR_814], lightheadedness) or new onset dyspnea should have an ECG performed. If atrial fibrillation persists, consider the risks and benefits of ibrutinib  treatment and dose 
modification. 
[IP_ADDRESS]  Second Primary Malignancies  
Other malignancies (range, 5 to 14%) including non- skin carcinomas 
(range, 1 to 3%) have occurred in patients treated with ibrutinib . The 
most frequent second primary malignancy was non -melanoma skin 
cancer (range, 4 to 11  %). 
[IP_ADDRESS]  T umor Lysis Syndrome 
Tumor lysis syndrome has been reported with ibrutinib therapy. Monitor 
patients closely and take appropriate precautions in patients at risk for tumor lysis syndrome (e.g. high tumor burden).  
In the recently published long- term follow -up for patients with MCL 
treated with single agent ibrutinib, the following recurrent serious adverse events were reported:  
Table 1-1 Ibrutinib: Recurrent Serious Adverse Events  
Total (N= 111) 
SAE*, n (%)  Any Grade  Grade 3-4 Grade 5  
Disease Progression  11 (10%)  3 (3%)  8 (7%)  
Pneumonia  8 (7%)  7 (6%)  1 (1%)  
Atrial Fibrillation  7 (6%)  6 (5%)  [ADDRESS_12118] Infection  4 (4%)  3 (3%)  0 
Febrile Neutropenia  3 (3%)  3 (3%)  0 
Abdominal Pain  3 (3%)  3 (3%)  0 
Acute Renal Failure  3 (3%)  2 (2%)  1 (1%)  
Subdural hematoma  3 (3%)  2 (2%)  0 
Pyrexia  3 (3%)  1 (1%)  0 
Confusional State  3 (3%)  1 (1%)  [ADDRESS_12119] decreased peripheral 
PrECOG Protocol Number: PrE0404 
Confidential  
Date: 8/21/2020  
 
19 neuropathy, allowing for an all oral therapy for patients with relapsed MCL. As a 
result, we will proceed with a phase I/II study of ixazomib and ibrutinib in 
combination for  relapsed/re fractory mantle cell lymphoma. The phase I portion of 
the study will be designed to identify the appropriate dose of ixazomib when 
combined with ibrutinib in this setting, and the phase II portion of the study will 
assess t he efficacy of this combination.  
1.5.[ADDRESS_12120] elected to enroll both BTK- pretreated and BTK- naïve patients for this 
study.  For the phase I portion of the study, which is focused primarily on safety and 
tolerability, all patients will be enrolled regardless of prior ibrutinib exposure.  
However, we will require ibrutinib pre-treated patients to satisfy specific criteria 
(Eligib ility Criteria  3.4) in order to avoid rapid progression during the first cycle of 
therapy which would make dose limiting toxicity assessment challenging.  
Phase I Summary : Three patients were enrolled to Dose Level 1 with no DLTs 
during the 28 day assessment period. Nine  patients were enrolled to Dose Level 2, 
five of the nine patients completed the 28 day assessment period with no DLTs.  
One patient experienced a grade 3 lung infection that was considered a DLT. Three 
of the nine  patients were not evaluable for DLT and were replaced. One patient was 
inadvertently given neulasta prior to rece iving Cycle 2, Day 1 therapy;  another 
patient unintentionally took Day 15 ixazomib on Day 9; and one patient forgot to 
take ibrutinib the last [ADDRESS_12121] developed two dosing cohorts ( BTK-
pretreated and BTK- naïve), so that we can assess the efficacy of this  combination 
in both settings. Based on the preclinical evidence of synergy, it is our hope and 
expectation that patients who have previously progressed on single agent ibrutinib 
or other BTK inhibitor will still achieve benefit when they receive the combination. Efficacy will be assessed separately for each cohort, with success determined based on historical cohorts.  For BTK- pretreated patients, we will use the previously 
reported CR rate for bortezomib, while for BTK- naïve patients we will compare our 
results to the previously reported single agent activity of ibrutinib, using CR rate as 
the primary endpoint.  
August 7 , 2020:  Phase II opened December 17, 2019 with Cohort A: BTK- naïve 
or Cohort B: BTK -pretreated.  
Enrollment to Cohort A: BTK -naïve will continue.  We plan to reach our original 
accrual goal of 36 BTK -naïve subjects treated at the established Dose Level 2 for 
31 eligible, treated patients. The Phase I BTK -naïve patients treated at Dose Level 
2 will be included in the 36 patient total. Seventeen additional BTK -naïve patients 
will be enrolled to complete this cohort.  
Enrollment to Cohort B: BTK -pretreated will close.  To date, only two patients 
have enrolled in Cohort B.  
PrECOG Protocol Number: PrE0404 
Confidential  
Date: 8/21/2020  
 
20 2. Study Objectives 
2.1 Primary Objective  
2.1.1  Phase I  
To determine the maximum tolerated dose (MTD)  of ixazomib in combination with 
ibrutinib in patients with relapsed/refractory mantle cell lymphoma (MCL) . 
2.1.2  Phase II  
To determine the complete response (CR) rate of ixazomib in combination with 
ibrutinib in relapsed/refractory MCL in BTK- naïve patients.  
2.2 Secondary Objectives 
2.2.1  Phase I  
• To evaluate regimen- related toxicities for the combination of ixazomib and 
ibrutinib in relapsed/refractory MCL. 
• To evaluate preliminary evidence of efficacy by [CONTACT_12680] (ORR) for the combination.  
• To evaluate evidence of efficacy by [CONTACT_12681]- free 
(PFS) and overall survival (OS) for patients treated with this combination.  
2.2.2  Phase II  
• To evaluate the ORR  of the combination of ixazomib and ibrutinib.  
• To evaluate PFS and OS for patients treated with the combination.  
• To further evaluate regimen- related toxicity for patients treated with ixazomib 
and ibrutinib.  
2.3 Exploratory Objectives  
  
 
  
 
  
 
  
 

PrECOG Protocol Number: PrE0404 
Confidential  
Date: 8/21/[ADDRESS_12122] to confirm a patient’s eligibility. For each patient, this 
checklist must be photocopi[INVESTIGATOR_530], completed and maintained in the patient’s chart.  
In calculating days of tests and measurements, the day a test or measurement is done is considered Day 0. Therefore, if a test is done on a Monday, the Monday four  weeks later 
would be considered Day 28.  
PrECOG Patient No.    
Patient’s Initials (  F, M, L )   
Physician Signature [CONTACT_12728]:  PrECOG  does not allow  waivers to any protocol specified criteria. A ll eligibility criteria listed 
in Section [ADDRESS_12123] . 
NOTE:  Institutions may use the eligibility checklist as source documentation if it has been reviewed, 
signed, and dated prior to registration by [CONTACT_12682] n. 
3.[ADDRESS_12124] a current or prior tissue sample that is IHC positive for cyclin D 1 or that is positive by [CONTACT_12683] t( 11;14).  
Date of  Relapse/Refractory MCL: _______________  
3.[ADDRESS_12125] been refractory to and/or relapsed/progressed after at least [ADDRESS_12126] Therapy: _______________  
3.[ADDRESS_12127] active grade 
II-IV acute GVHD or moderate/severe chronic GVHD by [CONTACT_12684]/or corticosteroids for the management of acute or chronic GVHD.  
3.4 Phase I: Prior proteasome inhibitor and/or Bruton’s tyrosine kinase inhibitors are allowed 
but patients may not have been exposed to the combination of proteasome inhibitor and BTK inhibitor.  Patients who have progressed on ibrutinib that are felt to be at high risk for 
rapid progression on this study shall not be eligible for the phase I portion of the study. 
NOTE:  Ibrutinib pre -treated patients must meet all eligibility criteria AND must have  
discontinued prior ibrutinib at least 3 months prior to starting study therapy.  
Pretreated with ibrutinib:  Yes   No 
If yes, does patient meet criteria above:   Yes  No 
PHASE I COMPLETED NOV EMBER 2 5, 2019.  
Phase I I: Prior proteasome inhibitor s allowed.  
(Please note prior to Version 3.0 of the protocol prior proteasome inhibitor and/or Bruton’s 
tyrosine kinase inhibitors were allowed but patients could not have been exposed to the 
combination of proteasome inhibitor and BTK inhibitor ). 
3.5 A ge ≥ 18 years.  _____  
_____  
_____  _____  
_____  
PrECOG Protocol Number: PrE0404 
Confidential  
Date: 8/21/2020  
 
22 3.6 ECOG performance status of 0-2 ( Appendix I). 
3.7 Ability to understand and willingness to sign IRB-approved informed consent.  
3.8 Willing to provide archived tumor tissue, bone marrow (if sufficient bone marrow and tumor 
tissue are available)  and blood samples for research (Section 13.0).  
3.9 Adequate organ function as measured by [CONTACT_4868], obtained ≤ 2 weeks prior to 
registration:  
• Absolute Neutrophil Count (ANC)  ≥ 750/mm3 
ANC: __________________ Date of Test: ____________ 
• Platelets  ˃50,000 /mm3 
Platelets: _______________ Date of Test: ____________ 
NOTE:  Platelet transfusions are not allowed within 3 days before registration to meet 
eligibility criteria.  
• Serum Creatinine  ≤ 2x Upper Limit Normal (ULN)  
Serum Creatinine : ________ ULN: ________  Date of Test : ___________  
• ALT and AST ≤ 3x ULN  
ALT: _________ Institution ULN: ________  Date of Test: __________  
AST: _________ Institution ULN: ________  Date of Test: __________  
• Total Bilirubin ≤ 1.5x ULN (in the absence of previously diagnosed Gilbert’s disease)  
Total Bilirubin: ___________ ULN: ________  Date of Test: ___________  
3.[ADDRESS_12128] not be pregnant or breastfeeding since we do not know the effects of ixazomib 
and ibrutinib on the fetus or breastfeeding child.  All sexually active females of childbearing 
potential (not surgically sterilized and between menarche and [ADDRESS_12129] menopause) must 
have a blood test to rule out pregnancy within 2 weeks prior to registration.  
Is the patient a woman of childbearing potential? _____________________ (yes/no)  
If yes, Date of Test: _______________  Results: ____________________________  
3.[ADDRESS_12130] agree to use 2 methods of adequate contraception (hormonal plus 
barrier or 2 barrier forms) OR abstinence prior to study entry, for the duration of study participation, and for [ADDRESS_12131] dose of study drugs . 
NOTE:  Should a woman become pregnant or suspect she is pregnant while participating in 
this study, she should inform her treating physician immediately.  
3.[ADDRESS_12132] resolved all prior non- hematologic toxicities assessed as related to prior 
therapy to ≤ grade 1. 
3.[ADDRESS_12133] measurable disease (i.e., ≥ 1.[ADDRESS_12134] diameter) by [CONTACT_12685].  Patients with extranodal involvement as the only measurable site of 
disease must have a largest diameter greater than ≥ 1.[ADDRESS_12135] be attributable to 
active lymphoma in the opi[INVESTIGATOR_871] . _____  
_____  
_____  
_____  
_____  
_____  
_____  _____  _____  
PrECOG Protocol Number: PrE0404 
Confidential  
Date: 8/21/[ADDRESS_12136] current/active C entral Nervous System (CNS)  involvement with 
mantle cell lymphoma (patients with prior CNS involvement are eligible as long as they have 
had no evidence of active CNS disease for at least 6 months).  Patients without cl inical 
evidence of CNS involvement do not require CNS assessment at screening.  
3.[ADDRESS_12137] another malignancy that could interfere with the evaluation of safety 
or efficacy of this combination. Patients with a prior malignancy will be allowed without study 
chair approval in the following circumstances:  
1) Not currently active and diagnosed at least 3 years prior to the date of enrollment . 
2) Non- invasive diseases such as low risk cervical cancer or any cancer in situ. 
3) Localized disease in which chemotherapy would not be indicated (such as Stage I 
colon, lung, prostate or breast cancer). Patients with other malignancies not meeting 
these criteria must be discussed with PrECOG  prior to enrollment.  
3.[ADDRESS_12138] 
7 days prior to treatment. Patients with a recent serious (grade ≥ 3) infection requiring 
hospi[INVESTIGATOR_12653] [ADDRESS_12139] evidence of uncontrolled cardiovascular conditions, including uncontrolled hypertension, uncontrolled cardiac arrhythmias, symptomatic congestive heart 
failure  (NYHA class III or higher  [Appendix I I]), unstable angina, or myocardial infarction 
within the past [ADDRESS_12140] 14 days before registration are allowed (except for 
patients who have had a myocardial infarction within 6 months).  
3.[ADDRESS_12141] dose of i brutinib with moderate or 
strong inhibitors of CYP3A ( Strong I nhibitors : ketoconazole, itraconazole, voriconazole, 
posaconazole, clarithromycin, and telithromycin; Moderate I nhibitors : fluconazole, 
darunavir, erythromycin, diltiazem, atazanavir, aprepi[INVESTIGATOR_053], amprenavir, fosamprenavir, crizotinib, imatinib, verapamil, ciprofloxacin, grapefruit juice products, and Seville oranges ) 
or strong CYP3A inducers  for ibrutinib and ixazomib ( carbamazepi[INVESTIGATOR_050], rifampin, phenytoin, 
St. John’s wort) . Refer to Section 11.2.7 for additional excluded medications and 
information.  
3.23 Patients with ongoing or active systemic infection, active hepatitis B or C virus infection, or known Human Immunodeficiency Virus  (HIV)  positive are not eligible. Testing is not required 
in absence of clinical suspi[INVESTIGATOR_2798].  
3.[ADDRESS_12142] a negative peripheral blood Polymerase 
Chain Reaction ( PCR ) and may not be posit ive for Hepatitis  B surface antigen. Patients with 
cirrhosis or other evidence of liver damage due to Hepatitis B or C are not eligible.  
3.25 Patients with any serious medical or psychiatric illness that could, in the investigator’s opi[INVESTIGATOR_1649], potentially interfere with the completion of the treatment according to the protocol are not eligible.  _____  
_____  
_____  
_____  
_____  
_____  
_____  
_____  
_____  
_____  
_____  
PrECOG Protocol Number: PrE0404 
Confidential  
Date: 8/21/2020  
 
24 3.26 Patients with a known allergy to any of the study medications, their analogues, or excipi[INVESTIGATOR_12654].  
3.27 Patients with known GI disease or prior GI procedure that could interfere with the oral absorption or tolerance of  ixazomib or ibrutinib  including difficulty swallowing are not eligible.  
3.28 Patients with ≥ Grade [ADDRESS_12143] be able to obtain ibrutinib through other means (i.e., commercially or through patient assistance programs). This must 
be confirmed prior to registration.  _____  
_____  
_____  
_____  
_____  
PrECOG Protocol Number: PrE0404 
Confidential  
Date: 8/21/[ADDRESS_12144] their origin 
in the current Declaration of Helsinki and will be consistent with applicable US regulatory requirements and International Conference on Harmonization/Good Clinical Practice (ICH/ GCP).  
The study will be conducted in compliance with the protocol. The protocol and any amendments and the patient informed consent will receive Institutional Review Board (IRB) 
approval prior to initiation of the study.  
Freely given written informed consent must be obtained from every patient or their legally 
acceptable representative prior to clinical trial participation, including informed consent for any screening procedures conducted to establish patient eligibility for the trial.  
Study personnel involved in conducting this trial will be qualified by [CONTACT_8640], training, and experience to perform their respective task(s).  This trial will not use the services of 
investigators or study personnel where sanctions have been invoked or where there has been scientific misconduct or fraud (e.g., loss of medical licensure, debarment). Investigators are responsible for the conduct of the study at their study site.  
4.[ADDRESS_12145] be 
submitted to PrECOG as noted in study materials. Detailed information regarding document submission and control is provided to each site in separate study materials.  
Once required documents are received, reviewed, and approved by [CONTACT_12686], a Study Reference Manual (SRM) will be forwarded to the site. Any changes to site regulatory documents must be submitted by [CONTACT_12687] y 
in a timely manner. Initial study drug shipment will not occur until the regulatory packet is 
complete. No patients will begin protocol therapy without formal registration as per the 
process below.  
4.[ADDRESS_12146] meet all of the eligibility requirements listed in Section 3 prior to registration. Treatment should begin ≤ 10 working days from study entry (date of registration).  
An eligibility checklist is included in Section 3. A confirmation of eligibility assessment by 
[CONTACT_1755]/or site will be performed during the registration process . 
Phase I Registration – Prior to discussing protocol entry with the patient AND  prior to 
registering in the electronic data capture (eDC) system, call the assigned PrECOG Project Manager to ensure that a place on the protocol is open to the patient.  An Enrollment 
Approval Form must be completed prior to registration.  
Upon determination that a subject meets eligibility criteria, the subject will be registered in 
the study by [CONTACT_12688] (eDC) system. Confirmation of 
registration will be displayed in the eDC system. Detailed registration procedures and study 
contac ts will be outlined in the SRM.  
The phase II portion will be conducted using the dose and schedule selected from the phase I portion of the study. Before proceeding to phase II, the protocol will be amended to specify 
the final dose selected from phase I.  Patients that participate in phase I will not  be eligible 
to participate in phase II.  
Phase II Registration  – After it is verified by [CONTACT_12689], registration  will occur by [CONTACT_12690] . 
PrECOG Protocol Number: PrE0404 
Confidential  
Date: 8/21/[ADDRESS_12147] not start protocol treatment prior to registration.  
4.4 Research Bone Marrow, Tissue and Blood Samples  
Mandatory bone marrow and tumor tissue samples are required at baseline (if sufficient 
bone marrow and tumor tissue are available, submission is mandatory) . 
Mandatory peripheral blood samples will also be collected.  
NOTE:  No bone marrow biopsy/aspi[INVESTIGATOR_12655].  
Time points  for bone marrow, tissue and blood samples are outlined in the study parameters 
(Section 10)  and specific requirements are outlined in the correlative section of this protocol 
(Section 13) and the lab manual.  
 
PrECOG Protocol Number: PrE0404 
Confidential  
Date: 8/21/[ADDRESS_12148] 3+3 design with the 
primary objective of determining the maximum tolerate dose (MTD)/recommended phase 2 
dose (RP2D) of this combin ation in MCL. Both ibrutinib- pretreated and ibrutinib- naïve 
patients will be enrolled. Planned dose levels are described below. There wi ll be no dose 
escalation above Dose L evel 2.  If dose level 1 is too toxic, we will de- escalate to dose level 
(-1). There shall be no dose reductions below dose level ( -1). 
 
 
    
 
 
   NOTE:  For the phase I portion of the study, ibrutinib pre -treated patients must meet 
all eligibility criteria AND must have discontinued prior ibrutinib  at least 3 
months prior to starting study therapy.  
Three patients were enrolled to Dose Level 1 with no DLTs during the 28 day assessment 
period. Nine patients were enrolled t o Dose Level 2. Five of the nine patients completed the 
28 day assessment period with no DLTs, and one patient experienced a Grade 3 lung 
infection that was considered a DLT. Three of the nine  patients  were not evaluable for DLT 
and were replaced. One patient was inadvertently given neulasta prior to receiving Cycle 2, Day 1 therapy ; another patient unintentionally took Day 15 ixazomib on Day 9; and one 
patient forgot to take ibrutinib the last 8 days of Cycle 1 unrelated to any toxicities . Phase I 
was completed November 2 5, 2019.  Dose Level 2 is the recommended Phase 2 dose.  
5.2 Phase II  
Once dose escalation and de- escalation has completed with determination of the 
MTD/RP2D  (Phase I completed November 2 5, 2019), the phase II portion of the study will 
begin. Patients will be enrolled to two cohorts,  based on prior BTK inhibitor treatment : BTK-
pretreated and BTK- naïve (see below) . Patients will be treated until disease progression or 
until unacceptable toxicity, with dose modifications and delays as described in Section 6.5. 
August 7 , 2020:  Phase II opened December 17, 2019 with  Cohort A: BTK- naïve or Cohort 
B: BTK- pretreated.  
Enrollment to Cohort A: BTK -naïve will continue.  We plan to reach our original accrual 
goal of 36 BTK -naïve subjects treated at the established Dose Level 2 for 31 eligible, treated 
patients. The Phase I BTK- naïve patients treated at Dose Level 2 will be included in the 36 
patient total. Seventeen additional BTK- naïve patients will be enrolled to complete this 
cohort.  
Enrollment to Cohort B: BTK -pretreated will close.  To date, only two patients have 
enrolled in Cohort B . Dose Level Ixazomib  
Days 1, 8, 15 of 
a 28 Day Cycle  Ibrutinib 
Days 1 -28 of a 
28 Day Cycle  
-1  3 mg 420 mg 
1 
Starting D ose 3 mg 560 mg 
2  4 mg 560 mg Open to Ibrutinib Naïve 
and Selected  Pretreated 
Patients  
PrECOG Protocol Number: PrE0404 
Confidential  
Date: 8/21/2020  
 
28  
 
  
 
 
  Ixazomib  
Days 1, 8, 15 of a 
28 Day Cycle  Ibrutinib 
Days 1 -28 of a 28 
Day Cycle  
4 mg  560 mg  Dosed at RP2D  
Cohort A: BTK-Naive  
Cohort  B: BTK -Pretreated : 
Closed to Enrollment 8/7/2020  
PrECOG Protocol Number: PrE0404 
Confidential  
Date: 8/21/2020  
 
29 6. Treatment Plan  
6.1 Overview  
This study shall be divided into phase I and phase II components. The phase I portion of 
the study shall be designed to evaluate the safety and tolerability of the combination of ibrutinib and ixazomib in relapsed/refractory MCL and to identify the MTD/RP2D. The phase 
II portion of the study will evaluate the efficacy of this combination.  
6.1.1  Ixazomib Administration  
Ixazomib will be administered orally. Patients should be instructed to swallow 
ixazomib  capsules whole, with water, and not to bre ak, chew, or open the capsules.  
Ixazomib  should be taken on an empty stomach (no food or drink) at least [ADDRESS_12149]  2 hours after food. Each capsule should be swallowed separately 
with a sip of water.  A total of approximately 8 ounces (240 mL) of water shou ld be 
taken with the capsules.  A Medication Diary will be provided to the patient to record 
each date and dose of ixazomib after Cycle 1 ( Appendix III). 
Missed doses can be taken as soon as the patient remembers if the next scheduled  
dose is ≥ 72 hours  for all cycles aside from Cycle 1 of the phase 1 study . Patients 
with dose delays in Phase I, Cycle 1 shall be managed as described below in 
Section 6.2 and Section 6.2.1. A double dose should not be taken to make up for a 
missed dose.  If the patient vomits after taking a dose, the patient should not repeat 
the dose but should resume dosing at the time of the next scheduled dose.  
Patients on Cycle 2 and beyond of the phase I study and those enrolled on the 
phase II study shall not make up any ixazomib doses that are delayed >[ADDRESS_12150] to food or drink  (except as noted in Section 6.6.2). Ibrutinib 
should be swallowed whole with water and the tablets should not be opened, broken, or chewed. A Medication Diary will be provided to the patient to record each date and dose of ibrutinib  (Appendix IV) . 
If a dose of ibrutinib is not taken at the scheduled time, it can be taken as soon as 
possible up to 8 hours after the scheduled time on the same day with a return to the normal schedule the following day. If a patient does not take a dose within 8 hours of the scheduled time, that day’s dose will be skipped. Extra capsules of ibrutinib should not be taken to make up for the missed dose.  If the patient vomits after taking 
a dose, the patient should not repeat the dose but should resume dosing at the time 
of the next scheduled dose.  
6.[ADDRESS_12151] 3 + 3 design. Eligible 
patients will include ibrutinib- naïve patients as well as selected  ibrutinib- pretreated patients.  
Given the focus of the phase I study on safety/tolerability, patients who have progressed on ibrutinib that are felt to be at high risk for rapid progression on this study shall not be eligible 
for the phase I portion of the study (Eligibility Criteria 3.4). This exclusion of rapid progressors is designed to decrease the risk of having to replace multiple patients due to progression during the dose- limiting toxicity ( DLT) assessment period.  
Dose escalation shall occur according to Table 6-1. The f irst thre e patients shall be accrued 
to Dose Level 1 (3  mg ixazomib and 560  mg ibrutinib). Patients shall take ibrutinib 
continuously once daily of a 28 day cycle . Ixazomib will be administered orally on days 1, 8, 
and 15 of a 28 day cycle.  Patients shall continue therapy until progres sion or unacceptable 
toxicity.  
PrECOG Protocol Number: PrE0404 
Confidential  
Date: 8/21/2020  
 
30  
    
 
  
 
The MTD/RP2D shall be defined as the highest dose level where [ADDRESS_12152] 6 patients experience 
a DLT, then that dose level shall be considered too toxic and dosing will occur at Dose Level 
(-1). If 2 or 3 patients experience a DLT at Dose Level (-1), the regimen will be considered 
too toxic and t he trial will end. If Dose Level 2 proves safe (0 or 1 DLT’s out of 3 patients), 
then an additional  3 patients shall be accrued to Dose Level 2. If 0- 1 out of 6 total patients 
treated at Dose Level 2 experience a DLT, then that dose level shall be considered the RP2D and the phase 1 study shall end. There shall be no dose escalation above Dose Level 
2. If 2 or 3 patients in Dose Level 2 experience a DLT, then that dose level shall be 
considered too toxic and Dose Level 1  shall be considered the RP2D  as long as 0 or 1 out 
of 6 patients experiences a DLT . 
Patients may delay  therapy  (ibrutinib and/or  ixazomib) up to [ADDRESS_12153] be >[ADDRESS_12154] a 3 day period between doses of ixazomib.  
Patients on Phase I, Cycle 2 and subsequent  cycles  shall not make up any ixazomib doses 
that are delayed >72 hours  due to toxicity ( missed doses can be taken as soon as the patient 
remembers if the next scheduled dose is [ADDRESS_12155]).  
For Cycle 1, patients should receive all ixazomib doses in clinic after a provider assessment. For all subsequent cycles, patients are only required to be seen in clinic on day 1 of the 
cycle  (NOTE:  Cycle 2 and Cyc le 3, Day 15 (and Day 22, if applicable) mandatory blood 
counts can be done  locally) . 
Three patients were enrolled to Dose Level 1 with no DLTs during the  28 day assessment 
period. Nine patients were enrolled t o Dose Level 2. Five of the nine patients completed the 
28 day assessment period with no DLTs, and one patient experienced a Grade 3 lung 
infection that was considered a DLT. Three of the nin e patients were not evaluable for DLT 
and were replaced. One patient was inadvertently given neulasta prior to receiving Cycle 2, Day 1 therapy;  another patient unintentionally took Day 15 ixazomib on Day 9; and one 
patient forgot to take ibrutinib the last 8 days of Cycle 1 unrelated to any toxicities . Phase I 
was completed November 2 5, 2019.  Dose Level 2 is the recommended Phase 2 dose.  
6.2.1  DLT Assessment  
Patients shall be assessed for  DLT through the conclusion of Cycle 1 (i.e., prior to 
Cycle 2, Day 1). Patients experiencing progression or who are non- adherent to the 
study regimen and/or assessments will be removed from study therapy and 
replaced for the purposes of DLT assessment.  Patients who miss 5 consecutive Table 6 -1 Dose Levels for Phase I Study 
Dose Level  Ixazomib  
Days 1, 8, 15 of 
a 28 Day Cycle  Ibrutinib 
Days 1 -28 of a 
28 Day Cycle  
-1  3 mg 420 mg 
1 
Starting D ose 3 mg 560 mg 
2  4 mg 560 mg 
PrECOG Protocol Number: PrE0404 
Confidential  
Date: 8/21/2020  
 
31 doses of ibrutinib for reasons unrelated to toxicity  OR who experience a dose delay 
of ixazomib of >72 hours for reasons unrelated to toxicity will not be considered 
DLT’s. These patients shall be replaced for the purposes of DLT assessment and determination of the MTD/RP2D but may continue study therapy at the discretion of the investigator.  DLT shall be defined according to Table 6-2. Patients who 
experience a DLT, may continue on study therapy. DLTs shall be managed 
according to S ection 6.5 detailing dose modifications/delays  and patient can re-start 
therapy once they meet criteria noted in Section 6.4. 
Table 6-2 Dose Limiting Toxicities for Phase I  
 Any toxicity -related dose delay >[ADDRESS_12156] cycle due 
to toxicity shall constitute a DLT. A delay of >7  days of the start of 
Cycle 2 due to toxicity shall also constitute a DLT.  
Grade 3 Non- Hematologic Toxicity aside from Grade 3 diarrhea, nausea, 
or vomiting which resolve within 48 hours of supportive care. 
Grade 3 Thrombocytopenia with significant bleeding (defined as acute 
bleeding requiring a transfusion and/or hospi[INVESTIGATOR_059]).  
Grade [ADDRESS_12157] remain febrile and neutropenic for >7 days. If a patient remains neutropenic but the fever resolves within 7 days, it shall not constitute a DLT.  
Grade 4  Non- Hematologic Toxicity  
Grade 5 Any Toxicity  
6.3 Phase II Treatment Administration  
Once the MTD/RP2D is determined, the phase I portion of the study shall end and the phase 
II portion shall begin (Phase I completed November 25 , 2019) . For the phase II portion of 
the study, patients will be divided into two cohor ts: BTK- pretreated and BTK- naïve. All 
patients who have received one dose of ibrutinib or any BTK inhibitor  or more shall be 
assigned to the BTK- pretreated cohort.  August 7 , 2020 : BTK- pretreated cohort closed.  
Patients shall receive therapy at the RP2D : Ibrutinib [ADDRESS_12158] evidence of progression or unacceptable toxicity  or withdra wal of consent . 
Patients shall not make up any ixazomib doses that are delayed >72 hours  due to toxicity 
(missed doses can be taken as soon as the patient remembers if the next scheduled dose 
is [ADDRESS_12159]).  
For Cycle 1, patients should receive day 1 and day 15 ixazomib doses in clinic after a 
provider assessment. For Cycle 2 -7, patients are only required to be seen in clinic on day 1 
of the cycle.  
If patient s continue on study therapy after Cycle 6 , patients are  required to be seen in clinic  
every 12 weeks (Day 1 of every 3 cycles ) starting with Cycle 7 . 
 
PrECOG Protocol Number: PrE0404 
Confidential  
Date: 8/21/2020  
 
32 6.4 Criteria to Begin a New Cycle of Therapy  
Prior to starting a new cycle of treatment  (Cycle 2 onwards), all of the following criteria must 
be met:  
• ANC must be ≥ 1000/mm3 (>750 /mm3 if documented bone marrow involvement at study 
entry [Cycle 2 only ]). 
• Platelet count must be ≥ 75,000/mm3 (>50,000/mm3 if documented bone marrow 
involvement [Cycle  2 only ]). 
NOTE:  Patients with marrow involvement at study entry may start Cycle 2 with decreased 
ANC /platelet  counts as documented above. For all other cycles, the standard 
criteria to start a new cycle apply.  
• All other non- hematologic toxicity (except for alopecia, fatigue, and electrolyte/glucose 
abnormalities that are immediately reversible and/or not felt to be clinically significant ) 
deemed at least possibly related to study therapy must have resolved to ≤ Grade 1 or 
to the patient’s baseline condition. Study therapy related fatigue must be resolved to ≤ 
Grade 2.  
Patients failing to meet these criteria may be delayed for up to 3 weeks  (21 days)  and should 
be restarted at adjusted dose levels as described below. Growth factors , platelet and blood 
transfusions  may be used per institutional practice for all cycles except Cycle 1 of the phase 
1 study  (unless patient experiences a DLT) . 
6.5 Dose Delays & Modifications  
All toxicities should be graded according to the National Cancer Institute (NCI) 
Common Terminology C riteria for Adverse Events Version 5.0 (CTCAE V 5.0). A copy 
of the CTCAE  V5 .0 can be downloaded from the CTEP website 
(http://www.ctep.cancer.gov ). 
A +/-3 day window is allowed for scheduled ixazomib therapy, required tests and/or visit s 
except as otherwise noted. Delays due to holidays, weekends, bad weather or other 
unforeseen circumstances will be permitted. 
Patients who experience a dose delay  during Cycle 1 of the phase 1 study shall be managed 
as described above in Section 6.2 and Section 6.2.1. If a patient experiences a DLT and 
continues on study therapy , follow the dose delays & modifications guidelines as noted in 
this section.  Phase I completed November 25, 2019.  
Patients on Cycle 2 and beyond of the phase I study and those enrolled on the phase II 
study shall not make up any ixazomib doses that are delayed >[ADDRESS_12160], otherwise the dose shall be considered skipped and shall not be made 
up. 
NOTE: It is the intent of this protocol to preserve the full labeled dosing of ibrutinib whenever possible. With the exception of the specified toxicities noted  in 
Section 6.5.2, ibrutinib should be continued at full dose and on schedule for 
all patients, regard less of ixazomib delays or modifications. Patients who are 
unable to tolerate ixazomib at any dose level due to toxicity shall be removed from study therapy, except in cases of potential overlappi[INVESTIGATOR_12656] ( Table 6-6 ).
PrECOG Protocol Number: PrE0404 
Confidential  
Date: 8/21/2020  
 
33 6.5.1  Dose Reductions/Modifications for Ixazomib and Ibrutinib  
Table 6-3  Ixazomib  and Ibrutinib Dose Adjustments for Hematologic Toxicities  
Criteria  Action on Ixazomib  Action  on Ibrutinib  
Within -Cycle Dose Modifications    
• If platelet count ≤ 30 × 109/L or ANC ≤ 0.50 × 109/L on 
an ixazomib dosing day (other than Day 1) . • Ixazomib  dose should be withheld.  
• Complete blood count (CBC) with differential 
should be repeated at least twice weekly (with 
2 days between CBC’s) until  ANC and/or 
platelet counts have exceeded the pre-specified values (Section 6.4) 
required to 
initiate a treatment cycle on at least 2 
occasions.  
• Upon recovery, ixazomib may be reinitiat ed 
with 1  dose level reduction (Table 6-5). • If no recovery after reduct ion of ixazomib to 
2.3 mg, then reduce ibrutinib to 420 mg dose.  
• If no recovery on the 420  mg dose, then 
discontinue study therapy.  
Dose Modifications for Subsequent Treatment Cycles    
• Delay of > 2 weeks in the start of a subsequent cycle due 
to lack of toxicity recovery  (Section 6.4).  
• ANC ≤ 750  × 109/L and/or platelet count ≤ 50 × 109/L 
(except for Cycle 1 and Cycle 2; Section 6.4).  
• NOTE:  Patients requiring delay of ≤ 2 weeks before 
starting a cycle do not require a dose reduction unless a delay has been  required on more than 1 cycle, in 
which case the ixazomib dose should be decreased by [CONTACT_12691] (Table 6-5) .
 • Hold ixazomib until resolution as per criteria  
in Section 6.4 . 
• Upon recovery, reduce ixazomib 1 dose level  
(Table 6-5) . 
• The maximum delay before treatment should 
be discontinued will be 3 weeks or at the 
discretion of the principal investigator . • If no recovery after reduction of ixazomib to 
2.3 mg, then reduce ibrutinib to 420 mg dose.  
• If no recovery on the 420  mg dose, then 
discontinue study therapy.  
[IP_ADDRESS]  Hematologic  Guidelines for Subsequent Treatment Cycles with Ixazomib 
• For hematologic toxicity that occurs during a cycle but recover in time for the start of the next cycle:  
o If dose was reduced within the cycle, start the next cycle at  that same dose.  
o If due to toxicity timing, i.e., after Day [ADDRESS_12161] severe toxicity.  
PrECOG Protocol Number: PrE0404 
Confidential  
Date: 8/21/2020  
 
34 Table 6-4 Ixazomib  and Ibrutinib Treatment Modification (Delays, Reductions, and Discontinuations) Due to Non-Hematologic 
Adverse Events  
Adverse Event (Severity)  Action on Ixazomib  Action on Ibrutinib  Further Considerations  
Peripheral Neuropathy     
• Grade 1 peripheral neuropathy  (PN) 
without pain  • No action. • NONE  Grade 1 signs and symptoms: 
asymptomatic; without pain or loss  
of function; clinical or diagnostic 
observations only.34 
• Grade 2  peripheral neuropathy or 
Grade 1 PN with pain  • Hold ixazomib until resolution to 
Grade ≤ 1 without pain or 
baseline . • NONE  Grade 2 signs and symptoms: 
Moderate symptoms; limiting 
instrumental  activities of daily living 
(ADL).34 
• New or worsening Grade 2 
peripheral neuropathy with pain or 
Grade 3  • Hold ixazomib until resolution to 
Grade ≤ 1 without pain or 
baseline . 
• Reduce ixazomib  to next lower 
dose upon recovery  
(Table 6-5). • NONE  Grade 3 signs and symptoms: 
severe symptoms; limiting self -care 
ADL; assistive device indicate d.34 
• New or worsening Grade 4 
peripheral neuropathy  • Discontinue ixazomib.  • NONE   
Grade 2 Non- Hematologic Toxicity 
that was Grade ≤ 1 at baseline. • Day 1 of cycle: Hold ixazomib 
until resolution to Grade ≤ 1 or 
baseline  (except for alopecia, 
fatigue and electrolyte/glucose 
abnormalities that are 
immediately reversible and/or 
not felt to be clinically 
significant).  
Day 8 and/or 15 of cycle: No 
change.  • NONE  Study therapy related to fatigue 
must be resolved to ≤ Grade 2 to continue treatment.  
PrECOG Protocol Number: PrE0404 
Confidential  
Date: 8/21/2020  
 
35 Table 6-4 Ixazomib  and Ibrutinib Treatment Modification (Delays, Reductions, and Discontinuations) Due to Non-Hematologic 
Adverse Events  
Adverse Event (Severity)  Action on Ixazomib  Action on Ibrutinib  Further Considerations  
Grade 3 Non- Hematologic Toxicity  • Hold ixazomib until resolution to 
Grade ≤ 1 or baseline. • NONE  See Section 6.5.2 for  dose 
reductions/ modifications for  
toxicities related to  ibrutinib.  
• If not recovered to ≤ Grade 1 or 
baseline within 2 weeks  • Reduce ixazomib to next lower 
dose upon return to ≤ Grade 1 
or baseline (Table 6-5).  • NONE   
• Subsequent recurrence Gra de 3 
that does not recover to ≤  Grade 1 
or baseline within 2 weeks  • Hold ixazomib until resolution to 
Grade < 1 or baseline . 
• Reduc e ixazomib to next lower 
dose (Table 6-5). • NONE  Monitor closely, take appropriate 
medical precautions, and provide 
appropriate symptomatic care. 
• Subsequent recurrence of Grade 3 
toxicity that does not recover to 
≤ Grade [ADDRESS_12162] dose level of ixazomib (GI 
toxicities ONLY)  • Continue ixazomib at lowest 
dose  • For GI toxicities ONLY 
(nausea, vomiting, or 
diarrhea) reduce dose of 
ibrutinib to 420 mg daily.  In this setting, ibrutinib shall not be 
reduced below 420 mg daily. If a 
patient cannot tolerate the 
combination of ixazomib 2.3 mg and 
ibrutinib 420 mg, they shall be 
removed from study therapy.  
Grade 4 Non- Hematologic Toxicity  • Consider permanently 
discontinuing ixazomib.  
• Discuss with  PrECOG and  
principal investigator . 
• If it is felt to be of potential 
clinical benefit to reinitiate 
therapy, patients should be 
managed per the Grade 3 non -
hematologic toxicity guidelines above.  • NONE  See Section 6.5.2 for dose 
reductions /modifications  for 
toxicities related to  ibrutinib.  
Exceptions are cases in which the 
investigator determines the patient 
is obtaining a clinical benefit.  
Patients who experience a recurrent 
grade 4 non-hematologic toxicity 
shall be permanently removed from study therapy.  
Patients requiring a delay of 2 weeks or less before starting a cycle do not require a dose reduction unless a delay has been  
required on more than 1 cycle, in which case the ixazomib dose should be decreased by [CONTACT_12691] (Table 6- 5). 
The maximum delay before treatment should be discontinued will be 3 weeks or at the discretion of the principal investigator.  
Once ixazomib is reduced for any toxicity, the dose may not be re -escalated.  If it is ultim ately determined that therapy 
with ixazomib is no longer safe, the patient will be removed from the study . 
PrECOG Protocol Number: PrE0404 
Confidential  
Date: 8/21/2020  
 
36 Table 6-5 Recommended Dose Modifications for Ixazomib  
6.5.2  Additional Dose Reductions/Modifications for I brutinib  
The following toxicities shall be considered related to ibrutinib and shall result in 
ibrutinib dose delay/modification per Table 6- 6: 
• Grade ≥ 3 Hemorrhage 
• Grade ≥ 3 Hypertension  
• Grade ≥ 3 Atrial Fibrillation  
• Grade ≥ 3 Arthralgias  
If a patient experiences any of these events, they should hold ibrutinib until recovery to grade ≤ 1 (or baseline) and subsequently shall modify the dose of ibrutinib as specified below in Table 6 -6. The occurrence of any of these events does not 
require a dose adjustment/delay of ixazomib if the investigator feels that continued therapy is appropriate and concomitant toxicities do not require a dose 
delay/modification of ixazomib.  
If at any time a patient experiences any  grade ≥ [ADDRESS_12163] possibly related to ibrutinib, the investigator should consider holding 
ibrutinib until the toxicity has resolved to grade ≤ 1 (or baseline). If upon reso lution 
the toxicity is still felt to be at least possibly related to ibrutinib, patients should be restarted on ibrutinib according to the instructions in Table 6- 6. An investigator may, 
at any time, permanently discontinue ibrutinib if they feel it is no longer safe to continue ibrutinib therapy. In this case, a patient may continue on ixazomib if felt to be benefitting from treatment. Any patient requiring discontinuation of ixazomib will be removed from study therapy.  
Table 6-6 : Dose Modifications for I brutinib  
Occurrence  Action for Ibrutinib  
First  Withhold ibrutinib until recover to grade ≤1 or baseline; 
may restart at original dose level . 
Second  Withhold ibrutinib until recover to grade ≤1 or baseline; 
may restart at 420 mg/day . 
Third  Withhold ibrutinib until recover to grade ≤1 or baseline; 
may restart at 280 mg/day  (only for above ≥ Grade 3 
toxicities) . 
Fourth Discontinue ibrutinib . 
Once a dose reduction of ibrutinib has occurred, there shall be no re- escalation of 
the ibrutinib dos e in future cycles. Patients requiring discontinuation of ibrutinib may 
remain on study therapy with ixazomib alone if they are felt to be receiving clinical 
benefit and are otherwise eligible to continue study therapy.  Patients requiring 
discontinuation of ixazomib will be removed from the study.   Starting Dose  Modification  
Dose  Level  4.0 mg 3.0 mg 
Dose Level  3.0 mg 2.3 mg 
Dose Level  2.3 mg Remove from study  
PrECOG Protocol Number: PrE0404 
Confidential  
Date: 8/21/2020  
 
37 All toxicities (including ibrutinib -specific toxicities) shall be managed with 
appropriate supportive care and expert consultation as indicated. Patients may 
remain on study therapy if these are able to be medically managed and resolve to grade ≤ 1 with therapy. Anti -platelet therapy or anti -coagulation is allowed for 
patients experiencing atrial fibrillation as long as Warfarin is not used.  
6.6 Concurrent Therapi[INVESTIGATOR_014]  
6.6.1  Required and/or Permitted 
The following medications and procedures are permitted during the study:  
• Antiemetics, including 5- HT3 serotonin receptor antagonists, may be used at 
the discretion of the investigator.  
• Loperamide or other antidiarrheal should be used for symptomatic diarrhea at 
discretion of the investigator. The dose and regimen will be according to 
institutional guidelines. IV fluids  should be given to prevent volume depletion.  
• Growth factors (e.g. , granulocyte colony stimulating factor [G -CSF], granulocyte 
macrophage- colony stimulating factor [GM- CSF], recombinant erythropoietin) 
are permitted except for Cycle 1 of the phase 1 study  (unless patient  
experiences a DLT). Their use should follow ASCO  guidelines and/or 
institutio nal practice.  
• Patients should be transfused with red cells and platelet s as clinically indicated 
and according to institutional guidelines.  However, transfusions may not be 
used to satisfy inclusion criteria for study entry.  
• Antiviral therapy such as acyclovir may be administered if medically 
appropriate.  
• Patients who experience worsening neuropathy from baseline may be observed 
for recovery, and have dose reductions/delays as indicated in the protocol, and any supportive therapy or intervention may be initiated as appropriate at the 
discretion of the investigator.  
• Supportive measures consistent with optimal patient care may be given 
throughout the study.  
6.6.2  Not Permitted 
Strong CYP3A inducers  should be avoided  during treatment with ixazomib and/or 
ibrutinib : 
• Avoid concom itant administration with strong CYP3A inducers (such as 
rifampin, phenytoin, carbamazepi[INVESTIGATOR_050], and St. John’s Wort).  
Systemic treatment with any of the above metabolizing enzyme inducers should be 
avoided, unless there is no appropriate alternative medication for the patient’s use 
(Rationale: If there were to be a drug- drug interaction with an inducer, ixazom ib 
and/or ibrutinib exposure would be decreased; the refore, there would be a reduced 
chance of an AE. However, there may be less chance for an antitumor effect, but that is not an absolute reason to be taken off ixazomib and/or ibrutinib) . 
Strong or moderate CYP3A inhibitors  should be avoided during treatment with 
ibrutinib:  
• Concomitant use of strong CYP3A inhibitors which would be taken chronically 
(e.g., ritonavir, indinavir, nelfinavir, saquinavir, boceprevir, telaprevir, 
nefazodone) is not recommended.  
• For strong CYP3A inhibitors used short -term (e.g., a ntifungals and antibiotics for  
7 days  or less, e.g., ketoconazole,  itraconazole, voriconazole,  posaconazole, 
PrECOG Protocol Number: PrE0404 
Confidential  
Date: 8/21/2020  
 
38 clarithromycin,  telithromycin) consider interrupting ibrutinib therapy during the 
duration of inhibitor use.  
• Reduce ibrutinib to [ADDRESS_12164] be used (e.g., 
fluconazole, darunavir, erythromycin, diltiazem, atazanavir, aprepi[INVESTIGATOR_053], 
amprenavir, fosamprenavir, crizotinib, imatinib, verapamil, and ciprofloxacin).  
• Avoid grapefruit and Seville oranges during ibrutinib treatment,  as these contain  
moderate inhibitors of  CYP3A . 
Patients  taking concomitant strong or moderate CYP3A4 inhibitors should be 
monitored more closely for signs of i brutinib toxicity . 
The following procedures are prohibited during the study.  
• Any antineoplastic treatment with activity against lymphoma, other  than study 
drugs . This includes corticosteroids which should not be used with the intent to 
treat the underlying lymphoma for a patient who has initiated study therapy . 
Corticosteroid use as an anti -emetic or  for other non- malignant etiologies may 
be used but should be limited to the smallest dose and duration required and 
should be documented.  
• Radiation therapy (note that, in general, the requirement for local radiation 
therapy indicates disease progression) . 
• Platelet transfusions to help patients meet eligibility criteria are not allowed 
within 3 days prior to study drug dosing for any dosing day . 
• Major surgery will be allowed as clinically indicated with a [ADDRESS_12165] to be discontinued for surgery but one dose may be missed if the patient is unable to take the dose due to the surgery (or if the treating investigator feels it is in the patient’s best interest to miss the dose). If more than one dose of ixazomib will need to be missed, this should be 
discussed with PrECOG . 
  
PrECOG Protocol Number: PrE0404 
Confidential  
Date: 8/21/2020  
 
39 7. S tudy Duration and Discontinuation of Therapy 
7.1 Study Duration  
Patients will receive protocol therapy unless:  
1. Disease progression per LUGANO criteria  or clinical progression.  
2. Toxicities considered unacceptable by [CONTACT_12692], despi[INVESTIGATOR_12657] . 
3. Any requirement to discontinue ixazomib based on dose modification guidelines in Section 6.5.1 . 
4. Development of an inter -current illness that prevents further administration of study 
treatment . 
5. Extraordinary Medical Circumstances: If at any time the constraints of this protocol are detrimental to the patient's health, protocol treatment should be discontinued.  
6. Patient withdraws consent  or is unable to comply with study procedures . 
7.[ADDRESS_12166] dose of study medication.  However, if a patient experiences an adverse event >[ADDRESS_12167] 
dose of study medication that is felt to be, in the opi[INVESTIGATOR_871], possibly, probably or definitely related to study therapy, the adverse event should be repor ted. 
If a patient  is removed from treatment for reason(s) other than progression, follow with 
regular tumor assessments per standard of care until progression or start of new treatment.  
For patients who are registered but do not receive any protocol therapy, baseline and follow -
up information per Section 10 will be collected.  
7.3 Criteria for Removal from Study Treatment  
A genuine effort will be made to determine the reason(s) why a patient fails to return for the necessary visits or is discontinued from the trial, should this occur. It will be documented 
whether or not each patient completed the clinical study. If for any patient study treatment 
or observations were discontinued , the reason will be recorded on the appropriate electronic 
case report form.  Reasons that a patient may discontinue treatment  in a clinical study are 
considered to constitute one of the following:  
1. Recurrence of disease or documented progression of disease ( with the exception of 
progressive lymphocytosis without any other evidence of disease progression). 
2. Intercurrent illness that prevents further administration of treatment per investigator discretion.  
3. Unacceptable adverse events  and/or occurrence of dose limiting toxicity . 
4. Treatment interruption of more than 3 weeks . 
5. Investigator and/or patient discontinue chemotherapy . 
6. Pregnancy.  
7. Develops a second malignancy (except for non- melanoma skin cancer or cervical 
carcinoma in- situ) that requires treatment, which would interfere with this study . 
8. The patient may choose to withdraw from the study at any time for any reason.  
9. General or specific changes  in the patient's condition that render the patient 
unacceptable for further treatment in the judgment of the investig ator. 
PrECOG Protocol Number: PrE0404 
Confidential  
Date: 8/21/[ADDRESS_12168] one dos e of ixazomib or ibrutinib will be included in the 
safety analysis. Patients who discontinue study treatment early should be followed for 
response assessments , if possible. Follow -up will continue per Section 10, as applicable.  
PrECOG Protocol Number: PrE0404 
Confidential  
Date: 8/21/2020  
 
41 8. Adverse Event Reporting 
8.1 Collection of Safety Informatio n 
Adverse Event  (AE) is defined as any new untoward medical occurrence or worsening of 
a pre- existing medical condition in a patient administered a medicinal product in a clinical 
investigation and which does not necessarily have a causal relationship with this treatment. 
An AE can therefore be any unfavorable and unintended sign (e.g., including an abnormal 
laboratory finding), symptom, or disease temporally associated with the use of a product (investigational or marketed), whether or not considered relat ed to the product 
(investigational or marketed).  
After informed consent, but prior to initiation of study treatment  (ixazomib and ibrutinib) , only 
AEs/SAEs caused by a protocol -mandated intervention will be collected (e.g., SAEs related 
to invasive procedures such as biopsies). After the initiation of study treatment, all identified AEs and SAEs must be recorded and described on the appropriate page of the electronic 
Case Report Form (eCRF). If known, the diagnosis  of the underlying illness or disorder 
should be recorded, rather than individual symptoms. The following information should be documented for all AEs: date of onset and resolution, severity of the event; the investigator’s 
opi[INVESTIGATOR_12658] (see definitions below); treatment 
required for the AE treatment required for the AE; cause of the event (if known); and information regarding resolution/outcome.  
Only clinically s ignificant laboratory abnormalities that require active management will be 
recorded as AEs or SAEs on the  eCRF (e.g., abnormalities that require  study drug dose 
modification, discontinuation of study treatment, more- frequent follow -up assessments, 
further diagnostic investigation, etc.).  
If the clinically significant laboratory abnormality is a sign of a disease or syndrome (e.g., alkaline phosphatase and bilirubin 5x the ULN associated with cholecystitis), only the 
diagnosis (e.g., cholecystitis) needs to be recorded on the Adverse Event eCRF.  
If the clinically significant laboratory abnormality is not a sign of a disease or syndrome, the abnormality itself should be recorded as an AE or SAE on the eCRF. If the laboratory abnormality can be characterized by  a precise clinical term, the clinical term should be 
recorded as the AE or SAE. For example, an elevated serum potassium level of 7.0 mEq/L 
should be recorded as “hyperkalemia” . 
Observations of the same clinically significant laboratory abnormality from v isit to visit 
should not be repeatedly recorded as AEs or SAEs on the eCRF unless their severity, seriousness, or etiology changes.  
Severity 
The categories and definitions of severity used for clinical trials AEs are defined in the NCI’s 
Common Terminology  Criteria (CTCAE) V 5.0 (http://www.ctep.cancer.gov) . 
Attribution  
The following categories and definitions of causal relationship or attribution to study drug 
should be used to assess Adverse Events:  
• Definite: There is a reasonable causal relationship between the study drug and the event. 
The event response to withdrawal of study drug (dechallenge) and recurs with 
rechallenge, if clinically feasible.  
• Probable: There is a reasonable causal relationship between the study drug and the 
event. The event responds to dechallenge. Rechallenge is not required.  
• Possible: There is a reasonable causal relationship between the study drug and the 
event. Dechallenge information is lacking or unclear.  
• Unlikely: There is doubtful causal relationship between the study drug and the event.  
PrECOG Protocol Number: PrE0404 
Confidential  
Date: 8/21/2020  
 
42 • Unrelated: There is clearly not a causal relationship between the study drug and the 
event or there is a causal relationship between another drug, concurrent disease, or 
circumstances and the event.  
Categories ‘definite’, ‘probable’ and ‘possible’ are considered study drug related. Categories 
‘unlikely’ and ‘unrelated’ are considered not study drug- related.  
The development of a new cancer should be regarded as an AE. New cancers are those that are not the primary reason for administration of study treatment and have been identified after inclusion of the patient into the clinical study.  
AEs related to ibrutinib and ixazomib should be followed for [ADDRESS_12169] dose 
of study therapy  until ≤ grade 1  or stabilization, and reported as SAEs if th ey become 
serious . Any AE’s (serious or not) that occur more than [ADDRESS_12170] possibly related to study therapy shall be reported.  
8.2 Handling of Serious Adverse Events (SAEs)  
8.2.[ADDRESS_12171] medical occurrence occurring after initiation of study 
treatment  or that at any dose: 
• results in death,  
• is life -threatening (defined as an event in which the study patient was at risk of 
death at the time of the event; it does  not refer to an event which hypothetically 
might have caused death if it were more severe),  
• requires inpatient hospi[INVESTIGATOR_312],  
• results in persistent or significant disability/incapacity,  
• is a congenital anomaly/birth defect,  
• is an important medical event (defined as a medical event(s) that may not be 
immediately life -threatening or result in death or hospi[INVESTIGATOR_313], based upon 
appropriate medical and scientific judgment, may jeopardize the patient or  may 
require intervention (e.g., medical, surgical) to prevent one of the other serious outcomes listed in the definition above).  
Examples of such events include, but are not limited to, intensive treatment in an 
emergency room or at home for allergic bronchospasm; blood dyscrasias or convulsions that do not result in hospi[INVESTIGATOR_059].  
8.3 SAE Reporting Requirements  
Serious adverse events (SAE) are defined above. The investigator should inform PrECOG 
of any SAE within [ADDRESS_12172] 
be completed and supplied to PrECOG within 24 hours/[ADDRESS_12173] be as complete as possible, including details 
of the current illness and (serious) adverse event, and an assessment of the causal relationship between the event and the investigational product(s). Information not available 
at the time of the initial report (e.g., an end date for the adverse event or laboratory values 
received after the report) must be documented on a follow -up PrECOG SAE report form. A 
final report to document resolution of the SAE is required. The investigator is responsible 
for following all SAEs un til resolution, until the subject returns to baseline status, or until the 
condition has stabilized with the expectation that it will remain chronic, even if this extends 
beyond study participation.  A copy of the transmission confirmation of the SAE report  to 
PrECOG should be attached to the SAE and retained with the patient records.  
PrECOG Protocol Number: PrE0404 
Confidential  
Date: 8/21/2020  
 
43 SAEs  should be  scanned and emailed to [EMAIL_220]  as per the 
instructions found in study materials provided to the investigator sit e. 
 
Medical Monitor  
During normal business hours  
(8:30 am -5:[ADDRESS_12174]):  
Phone: 610- 354-0404 
After normal business hours:  
Phone:  [PHONE_224] 
Email:  Manager, Clinical Safety  
During normal business hours  
(8:30 am -5:[ADDRESS_12175]):  
Phone: 610- 354-0404 
After normal business hours:  
Cell: [PHONE_224]  
PrECOG will notify  [COMPANY_005] Pharmacovigilance (or designee)  of all SAE’s within 24 hours of 
PrECOG’s  & Investigator’s  Awareness Date as discussed above. Relevant follow -up 
informati on will be provided to [COMPANY_005] as soon as it becomes available.  
Investigators should also report event(s) to their IRB as required.  
Collection of complete information concerning SAEs is extremely important. Full 
descriptions of each event will be followed. Thus, follow -up information which becomes 
available as the SAE evolves, as well as supporting documentation (e.g., hospi[INVESTIGATOR_12659]), should be collected subsequently, if not available at the 
time of the initial report, and immediately sent using the same procedure as the initial SAE report.  
All SAEs, regardless of causality, must be collected which occur within [ADDRESS_12176] . 
NOTE:  After study closure, study -drug related SAEs should be reported voluntarily by [CONTACT_12693] . 
Serious adverse event reporting to regulatory authorities and all participating i nvestigators 
will be conduc ted by [CONTACT_12694]  (or designee) in accordance with 21CFR312.32, local 
requirements  and international regulations, as appropriate.  FDA reporting requirement 
timelines will be followed.  PrECOG will also concurrently forward any such reports to 
[COMPANY_005]. 
8.3.[ADDRESS_12177] be 
reported to PrECOG  on a Second Primary Cancer  form within 30 days of diagnosis , 
regardless of relationship to protocol treatment. Secondary primary malignancies should 
also be reported as a SAE. The SAE form is not for use for reporting recurrence or 

PrECOG Protocol Number: PrE0404 
Confidential  
Date: 8/21/2020  
 
44 development of metastatic disease. A copy of the pathology report, if applicable, should be 
sent, if available.  
NOTE : Once data regarding survival and remission status are no longer required by [CONTACT_12695], no follow -up data should be submitted.  
8.5 Procedures in Case of Pregnancy  
Prior to study enrollment, women of childbearing potential (WOCBP) and male patients with 
a female partner of childbearing potential must be advised of the importance of avoiding pregnancy during trial participation and the potential risk factors for an unintentional pregnancy, documented in the informed consent. In addition, all WOCBP should be instructed to contact [CONTACT_12696] 
(e.g., missed or late menstrual period) at any time during study participation.  
Pregnancy of a female patient or the female partner of  a male patient  occurring whil e the 
patient is receiving study drug or within 3 months  after the patient’s last dose of study drug 
will be reported to PrECOG on a Pregnancy Form within 24 hours of the investigator’s 
knowledge of the pregnancy.  
All reports of congenital abnormalities/birth defects and spontaneous miscarriages should 
also be reported and handled as SAEs. Elective abortions without complications should not 
be handled as AEs.  
The outcome of all pregnancies (spontaneous miscarriage, elective termination, normal birth including health of the newborn or congenital abnormality) must be followed and documented on the Pregnancy Form even if the subject was discontinued from the study treatment. Should pregnancy occur during a subject’s participation, the subject will 
immediately be discontinued from the treatment and followed per protocol.  
The study -specific Pregnancy F orm can be found in the Study Reference Manual.  
PrECOG Protocol Number: PrE0404 
Confidential  
Date: 8/21/[ADDRESS_12178]  
LUGANO Classification  
All disease response evaluation shall occur  according to the Lugano classification35. 
9.1 Scheduled Restaging Studies  
All patients shall complete a PET/CT at  the time of study enrollment. Thereafter, restaging 
shall include CT chest/abdomen/pelvis after cycles 3, 6, 9, and 12, and then every 6 months 
while on study therapy. PET/CT  or MRI  may be substituted for CT at the discretion of the 
treating investigator, especially in cases where lesions are not readily noted on CT . Patients 
who discontinue study therapy for reasons other than disease progression shall have CT’s 
performed every 6 months until progression and/or initiation of a new therapy.  
All patients with suspected CR based on routine restaging should have a PET/CT 
performed to confirm CR.  
9.2 Complete Response (CR)  
In order to satisfy the criteria for a complete response, patients who undergo CT scan only 
must meet the following criteria:  
• Target nodes/nodal masses must regress to ≤1.[ADDRESS_12179] transverse diameter . 
• No extralymphatic sites of disease. 
• Absent non- measured lesions . 
• All organ enlargement must be regressed to normal . 
• No new lesions . 
• Bone marrow must be normal by [CONTACT_5293] (must be evaluated at the time of 
suspected CR in patients with a positive bone marrow at enrollment) . 
Patients undergoing a PET/CT must meet the following cr iteria:  
• Deauville score of 1, 2 or 3 on the 5- point scale . 
• No new lesions . 
• No evidence of FDG avid disease in the bone marrow . 
NOTE:  ALL PATIENTS WITH SUSPECTED CR WHO HAD BONE MARROW INVOLVEMENT AT SCREENING MUST UNDERGO A BONE MARROW BIOPSY 
TO CONFIRM RE SPONSE.  
9.3 Partial Response (PR)  
Patients undergoing a CT must meet the following criteria for PR:  
• ≥ 50% decrease in the sum of the product of the diameters  (SPD) of up to 6 target 
measurable nodes and extranodal sites.  
• Lesions too small to measure on CT should be considered 5 mm x 5  mm as the default 
value.  
• Lesions that are no longer visible should be considered 0 mm x 0  mm. 
• Non- measured lesions should be absent/normal or regressed, but without increase. 
• Spleen, if previously enlarged, must  have regressed by >50% in length beyond normal. 
Patients undergoing PET/CT must meet the following criteria for PR:  
• Deauville score of 4 or 5 with reduced uptake compared to baseline and residual masses of any size.  
 
 
PrECOG Protocol Number: PrE0404 
Confidential  
Date: 8/21/2020  
 
46 • Bone marrow with residual uptake higher than uptake in normal marrow but reduced 
compared to  baseline (diffuse uptake compatible with reactive changes from 
chemotherapy is allowed). If there are persistent focal changes in the marrow in the context of a nodal response, consideration should be given to further evaluation with MRI or biopsy or an interval scan.  
9.4 No R esponse/ Stable Disease  (SD) 
Patients undergoing CT must meet the following criteria for SD/No response:  
• <50% decrease from baseline in SPD of up to 6 dominant, measurable nodes and 
extranodal sites;  no criteria for progressive disease are met.  
• No increase of non- measured lesions or organ enlargement consistent with 
progression . 
Patie nts undergoing PET/CT must meet the following criteria for SD/No response:  
• Deauville score of 4 or 5 with no significant change in FDG uptake from baseline at 
interim or end of treatment.  
• No change in FDG activity of bone marrow from baseline. 
9.5 Progressive Disease (PD) 
Patients undergoing CT must meet one of the following criteria for PD:  
• An individual node/lesion must be abnormal with the following:  
o Longest diameter > 1.5 cm and  
o Increase by ≥ 50% from the cross product of the longest diameter and perpendicular 
diameter nadir and  
o Increase in the longest diameter or shortest diameter from nadir:  
 0.5 cm for lesions ≤ 2 cm 
 1.0 cm for lesions > 2cm 
• For patients with splenomegaly, the splenic length must increase by >50% of the extent of its  prior increase above baseline.  If no prior splenomegaly, it must increase by [CONTACT_12697] 2 cm from baseline.  
• New or recurrent splenomegaly . 
• New or clear progression of pre- existing non- measured lesions . 
• Regrowth of previously resolved lesions . 
• A new node > 1.5 cm in any axis . 
• A new extranodal site > 1.0 cm in any axis; if < 1.[ADDRESS_12180] be attributable to lymphoma. 
• Assessable disease of any size unequivocally attributable to lymphoma. 
• New or recurrent bone marrow involvement . 
Patients undergoing PET/CT must meet one of the following criteria for PD:  
• Deauville score of 4 or 5 with an increase in intensity of uptake from baseline. 
• New FDG -avid foci consistent with lymphoma (If uncertain regarding the etiology of a 
new lesion, biopsy or interval scan may be considered) . 
NOTE:  Patients with isolated lymphocytosis shall not constitute progression in the absence 
of other findings.  
 
PrECOG Protocol Number: PrE0404 
Confidential  
Date: 8/21/2020  
 
47 9.6 Criteria for PET/CT R eporting  
Patients who undergo PET /CT as part of their interim, on- treatment, and end of treatment 
staging assessments should be assessed according to the following scoring system.  
1. No uptake above bac kground. 
2. Uptake ≤ mediastinum . 
3. Uptake >mediastinum but ≤ liver. 
4. Uptake moderately greater than liver . 
5. Uptake markedly higher than liver and/or new lesions . 
X N ew areas of uptake unlikely to be related to lymphoma. 
For further information regarding the Deauville scoring system, please refer to Barrington et al, J 
Clin Oncol 201435. 
PrECOG Protocol Number: PrE0404 
Confidential  
Date: 8/21/2020  
 
48 10. Study Parameters  
1. All pre -study scans should be done ≤ 4 weeks prior to registration.  
2. All other pre- study assessments should be done ≤ 2 weeks prior to registration.  
Procedures  Screening  Cycle 1* 
(1 cycle=28 Days)  Cycle 2-Cycle 6* Cycle 7 and 
Subsequent 
Cycles12* Every 3 
Cycles* Off 
Treatment14 Follow -
Up16 Day 1  
+/- 1 
day Day 8  
+/- 1 
day Day 15  
+/- 1 
day Day 22  Day 1  
+/- 3 
days  Day 8 
+/- 3 
days  Day 15  
+/- 3 
days  Day 22 
BREAK  Day 1  
Every 12 
Weeks  
Written Informed Consent  X             
Disease Characteristics1 X             
Medical/Surgical History  X             
Assessment of Baseline 
Signs & Symptoms  X             
Height  X             
Physical Exam including 
Weight  X X  X  X    X12  X  
Vital Signs  
(Temperature, Pulse, 
Blood Pressure)  X X  X  X    X12  X  
Performance Status  X X    X    X12  X  
CBC/Differential/Platelets2 X X  X X X2  X2  X2  X  
Chemistry3 X X  X  X3    X3  X  
PT/INR  X             
Lactate Dehydrogenase 
(LDH)  X             
Vitamin D Level4 X             
Peripheral Blood Flow 
Cytometry  X             
Serum Pregnancy Test5 X             
PET/CT X             
Chest/Abdomen/Pelvic 
MRI or CT6           X13 X  
Bone Marrow Aspi[INVESTIGATOR_12660]7 X           X7  
PrECOG Protocol Number: PrE0404 
Confidential  
Date: 8/21/2020  
 
49 Procedures  Screening  Cycle 1* 
(1 cycle=28 Days)  Cycle 2-Cycle 6* Cycle 7 and 
Subsequent 
Cycles12* Every 3 
Cycles* Off 
Treatment14 Follow -
Up16 Day 1  
+/- 1 
day Day 8  
+/- 1 
day Day 15  
+/- 1 
day Day 22  Day 1  
+/- 3 
days  Day 8 
+/- 3 
days  Day 15  
+/- 3 
days  Day 22 
BREAK  Day 1  
Every 12 
Weeks  
Bone Marrow 
Conventional 
Cytogenetics and FISH8 X             
Pathology Review with 
Ki67 Assessment9 X             
Research Specimens10  X10         X10 X10  
Treatment 
Administration11  X X11 X  X11 X11 X11  X11    
Concomitant Medication 
Review  X X  X  X    X12  X  
Adverse Events 
Assessment   X  X  X    X12  X15  
Survival Status              X 
* Scheduled Visits:  +/-3 day window is allowed for scheduled ixazomib therapy, required tests and/or visit s except as otherwise noted.  Delay due to holidays, 
weekends, bad weather or other unforeseen circumstances will be permitted.  
[ADDRESS_12181] date of diagnosis and stage . 
2 CBC with differential and platelet count which includes WBC, ANC, Platelets, Hemoglobin, and Hematocrit r equired as noted below . 
Phase I:  Days 1,  8, 15 and 22 of Cycle 1 ; Days 1 and 15 of Cycle 2 and Cycle 3 (patients with ANC <1000 and/or platelets <100,000 /mm3 on Day [ADDRESS_12182] blood counts done on Day 22 for Cycle 2 and 3 only ); and Day 1 of subsequent cycles . Phase I completed November 25, 2019.  
Phase II:  Days [ADDRESS_12183] additional labs drawn as clinically indicated at the discretion 
of the treating physician.  
3 Albumin, BUN/ creatinine, uric acid, sodium, potassium, chloride, glucose , calcium, alkaline phosphatase, AST, ALT, total bilirubin,  and total protein.  Days 1 
and 15 of Cycle 1 for which a clinic visit is required.  Patients will be required to be seen in clinic on Day 1 of Cycles 2-7, then every 3 cycles thereafter. Labs 
are only required on the days patients are seen in clinic.  
NOTE:  Patients with a history of hepatitis B or C must have a negative peripheral blood Polymerase Chain Reaction (PCR) and may not be positive for 
Hepatitis B surface antigen.  
 
PrECOG Protocol Number: PrE0404 
Confidential  
Date: 8/21/2020  
 
50 4 25(OH) Vi tamin  D level. 
5 Required for sexually active females of child -bearing potential.  
6 PET/CT ma y be substituted for CT  Chest/Abdomen/Pelvis at the discretion of the investigator.  
7 Bone Marrow Biopsy to include: Aspi[INVESTIGATOR_12661].  Bone marrow biopsy will be repeated at the time of 
suspected CR for patients with involvement at the time of enrollment. Optional bone marrow biopsies and aspi[INVESTIGATOR_12662]/or time of progression.  
8 Bone marrow  samples will be sent for conventional cytogenetics, FISH for t(11;14) and FISH for del(17p) [conventional cytogenetics,  FISH fo r t(11;14) and 
FISH for del(17p) may also be done on tumor tissue samples (nodal or extranodal) in lieu of or in addition to bone marrow rev iew]. 
[ADDRESS_12184] an assessment of Ki67 performed on available tissue.  Tissue 
used for pathology review should ideally be from the time of relapse but pre-treated tissue can be used if that is the only available sample.  
10 Research samples shall be obtained at the time of screening/study entry, after cycle 3, at time of susp ected CR, and at the end of therapy or time of  
progression.  Refer to Sect ion 13 for details.  
Screening/Study Entry  
Peripheral Blood: Two 6 mL in EDTA tubes  
Bone Marrow: One 10 mL in EDTA tube FFPE: Block p referred or 1 H&E slide plus 10 unstained slide s 
After Cycle 3 (up to  5 days before Cycle 4, Day 1)  
Peripheral Blood: Two 6 mL in EDTA tubes  
At time of Suspected CR  
Peripheral Blood: Two 6 mL in EDTA tubes  
End of Therapy/ At Time of Progression  (within [ADDRESS_12185] dose of study medication)  
Peripheral Blood: Two 6 mL in EDTA tubes  
NOTE:  If sufficient bone marrow and tumor tissue are available, submission is mandatory). No bone marrow biopsy/aspi[INVESTIGATOR_12663].  
11 Pati ents will receive ixazomib orally  on days 1, 8, and 15 of each 28 day cycle (1 cycle=28 days)  [Section 6.1.1 for dosing administration] . Ixazomib shall be 
administered in the clinic on C ycle 1, Day 1 and Cycle 1, Day 15 ( Day 8 can be administered at home) . For subsequent cycles, ixazomib doses on Days 8 
and 15 can be administered at home.  Ixazomib Medication Diary will be reviewed for compliance and collected every cycle after Cycle 1  (Appendix II I). Ibrutinib 
shall be administered orally daily on days 1-28  [Section 6.1.2 for dosing administration] . Ibrutinib Medication Diary will be reviewed for compliance and 
collected every cycle  (Appendix IV ). See Section 6.2 for Phase I and Section 6.3 for Phase II dosing instructions and Section 6.5  for dose delays/ modifications.  
NOTE:  If patient continues  on study therapy after Cycle 6, the visit schedule may be increased to every 3 cycles  starting with Cycle 7 and study medic ation 
will be dispensed for 3 cycles. Medication Diaries will be colle cted every 3 cycle s when patient returns to clinic . 
12 If patient continues  on study therapy after Cycle 6, the visit schedule may be inc reased  from 4 to 12 weeks  starting with Cycle 7 while receiving study therapy 
(Scan schedule will remain unchanged, see footnote 13) . Physical exam  with weight , vital signs , performance status , blood work, concomitant medication 
review and adverse events assessment  will be performed every 12 weeks (Day 1 of every 3 cycles) . 
 
PrECOG Protocol Number: PrE0404 
Confidential  
Date: 8/21/[ADDRESS_12186]/abdomen/pelvis (or PET/CT or MRI as clinically indicated per investigator discretion) after cycles 3, 6, 9, 
12 and subsequently every 6 months while on study therapy.  Scans should be performed during the 7 days preceding the following cycle (i.e., wi thin 7 days 
of Cycle 4, Day 1) . Patients with suspected CR should undergo PET/CT to confirm this. This can be done within [ADDRESS_12187] that 
initially demonstrates potential CR.  
14 Thirty (30) days +/ - [ADDRESS_12188] dose of study therapy . If patient is removed from treatment for reason(s) other than progression, follow with regular tumor 
assessments per standard of care until progression or start of new treatment . Once a patient has initiated a new therapy, no further study -related imaging 
assessments for this study are required.  
[ADDRESS_12189] subsequent therapy shall be reported. 
 
PrECOG Protocol Number: PrE0404 
Confidential  
Date: 8/21/2020  
 
52 11. Drug Formulation and Procurement  
11.1 Ixazomib36 
11.1.1  Other Names  
Ixazomib is also referred to as MLN9708 or MLN2238 . 
11.1.2  Classification  
Ixazomib is an oral proteasome inhibitor.  
11.1.3  Storage and Stability  
Upon receipt at the investigative site, ixazomib  should remain in the blister and carton 
provided until use or until drug is dispensed. The container should be stored at the 
investigative site; do not store above 86 °F (30°C ); do not freeze. Ensure that the drug 
is used before the retest expi[INVESTIGATOR_12664]. Expi[INVESTIGATOR_12665].  
Ixazomib  capsules dispensed to the patient for take- home dosing should remain in the 
blister packaging and refrigerated as noted above until the point of use. The 
investigative site is responsible for providing the medication to the patient in the correct 
daily dose configurations. Comprehensive instructions should be provided to the patient in order to ensure compliance with dosing procedures. Patients who are receiving take- home medication should be given only 1 cycle of medication at a time  
(starting with Cycle 7, may receive 3 cycles at a time). Patients should be instructed 
not to store the medication above 86°F  (30°C ); do not freeze f or the duration of each 
cycle. Patients should be instructed to return their empty blister packs to the 
investigative site, rather than discarding them. Reconciliation will occur accordingly when the patient returns for their next cycle of take- home medication. Any extreme in 
temperature should be reported as an excursion and should be dealt with on a case-by-case basis.  
Because ixazomib  is an investigational agent, it should be handled with due care. 
Patients should be instructed not to chew, break, or open capsules. In case of contact [CONTACT_12698], raising dust should be avoided during the clean- up operation. 
The product may be harmful by [CONTACT_12699], ingestion, or skin absorption. Gloves and protective clothing should be worn during cleanup and return of broken capsules and powder to minimize skin contact.  
The area should be ventilated and the site washed with soap and water after material pi[INVESTIGATOR_9696]-up is complete. The material should be disposed of as hazardous medical waste 
in compliance with federal, state, and local regulations.  
In case of contact [CONTACT_12700] (e.g. , from a broken capsule), skin should be 
washed immediately with soap and copi[INVESTIGATOR_12666] [ADDRESS_12190] capsules.  
11.1.4  Dose Specifics  
Ixazomib is dispensed in a 4- week supply  (starting with Cycle 7, may be dispensed in 
12-week supply) . The capsules will be individually packaged using cold- form foil -foil 
blisters that  are in child- resistant carton.  There will be 3 capsules in each wallet/carton.  
Patients will take one capsule on days 1, 8, and 15 of each cycle.  
Refer to Section 6.5.1  and Table 6- 3, Table 6-4 and Table 6-5 for Dose Delays and 
Modifications details.  
PrECOG Protocol Number: PrE0404 
Confidential  
Date: 8/21/2020  
 
53 11.1.5  Route of Administration  
Ixazomib will be administered orally. Patients should be instructed to swallow ixazomib  
capsules whole, with water, and not to break, chew, or open the capsules.  Ixazomib  
should be taken on an empty stomach (no food or drink) at least [ADDRESS_12191] 2 hours after food. Each capsule should be swallowed separately with a sip of 
water.  A total of approximately 8 ounces (240 mL) of water should be taken with the 
capsules.  
Missed doses can be taken as soon as the patient remembers if the next scheduled 
dose is [ADDRESS_12192]  for all cycles aside from Cycle 1 of the phase 1 portion 
of the study. Patients with dose delays in Cycle 1 shall be managed as described in 
Section 6.2.  A double dose should not be taken to make up for a missed dose.  If the 
patient vomits after taking a dose, the patient should not repeat the dose but should 
resume dosing at the time of the next scheduled dose.  
Ixazomib Medication Diary will be reviewed for compliance and collected every cycle for Cycle 1 -Cycle 6  (Appendix III). Starting with Cycle 7, Ixazomib Medication Diary 
will be reviewed  and collected every 3 cycles.  
11.1.6  Drug Interactions  
Avoid concomitant administration of ixazomib with strong CYP3A inducers (such as 
rifampin, phenytoin, carbamazepi[INVESTIGATOR_050], and St. John’s Wort).  
11.1.[ADDRESS_12193] is provided in strengths of 4.0- , 3.0- , and 2.3- mg capsules 
as the active boronic acid. The different dose strengths are differentiated by [CONTACT_12701]:  
Dose Strength  Capsule Size  Capsule Color  
4.0 mg Size 4  Ivory 
3.0 mg Size 3  Light gray  
2.3 mg Size 2  Light pi[INVESTIGATOR_12667]. As needed,  ixazomib may be requested by [CONTACT_458]  (or their authorized 
designees) at each participating institution. The investigator, or a responsible party 
designated by [CONTACT_093], must maintain a careful record of the receipt, 
disposition, and return/destruction (site’s drug destruction policy must be reviewed and approved by [CONTACT_12702] a site) of ixazomib.  
11.1.[ADDRESS_12194] access to this agent. Drug accountability will be performed by [CONTACT_12694].  
 
PrECOG Protocol Number: PrE0404 
Confidential  
Date: 8/21/[ADDRESS_12195] been associated with ixazomib  treatment.  Management 
guidelines regarding these events are outlined below. Further details of management of ixazomib  AEs are described in the ixazomib  IB. 
[IP_ADDRESS] Prophylaxis Against Risk of Reactivation of Herpes Infection  
Patients may be at an increased risk of infection including reactivation of herpes zost er and herpes simplex viruses. Antiviral therapy such as 
acyclovir, valacyclovir, or other antivirals may be initiated as clinically 
indicated.  
[IP_ADDRESS] Nausea and/or Vomiting  
Standard anti -emetics including 5- hydroxytryptamine 3 serotonin receptor 
antagonists are recommended for emesis if it occurs once treatment is initiated; prophylactic anti -emetics may also be considered at the 
physician’s discretion . Dexamethasone should not be administered as an 
anti-emetic. Fluid deficit should be corrected before initiation of study drug 
and during treatment.  
[IP_ADDRESS] Diarrhea  
Prophylactic antidiarrheals will not be used in this protocol. However, 
diarrhea should be managed according to clinical practice, including the administration of antidiarrheals once infectious causes are excluded. Fluid intake should be maintained to avoid dehydration. Fluid deficit should be 
corrected before initiation of treatment and during treatment.  
[IP_ADDRESS] Erythematous Rash With or Without Pruritus  
As with bortezomib, rash with or without pruritus has been reported with ixazomib, primarily at the hi gher doses tested and when given with agents 
where rash is an overlappi[INVESTIGATOR_5171]. The rash may range from limited 
erythematous areas, macular and/or small papular bumps that may or 
may not be pruritic over a few areas of the body, to a more generalized eruption that is predominately on the trunk or extremities.  Rash has been 
most commonly characterized as maculopapular or macular. To date, when it does occur, rash is most commonly reported within the first 3 cycles of therapy. The rash is often transient,  self-limiting, and is typi[INVESTIGATOR_12668] 1 to 2 in severity.  
Symptomatic measures such as antihistamines or corticosteroids (oral or topi[INVESTIGATOR_2855]) have been successfully used to manage rash and have been used prophylactically in subsequent cycles. The use of a topi[INVESTIGATOR_2855], IV, or oral steroid (e.g. , prednisone ≤ 10 mg per da y or equivalent) is permitted. 
Management of a Grade 3 rash may require intravenous anti histamines 
or corticosteroids. Administration of ixazomib (and/or other causative agent if given in combination) should be modified per protocol and re-initiated at a reduced level from where rash was noted (Table 6-4 ). 
In line with clinical practice, dermatology consult and biopsy of Grade 3 or higher rash or any SAE  involving rash is recommended.  Prophylactic  
measures should also be considered if a patient has previously developed 
a rash (e.g. , using a thick, alcohol -free emollient cream on dry areas of 
the body or or al or topi[INVESTIGATOR_12669]). Rare risks are Stevens -
Johnson Syndrome, a severe and potential ly life -threatening rash with 
skin peeling and mouth sores, toxic epi[INVESTIGATOR_194] (TEN) and drug 
PrECOG Protocol Number: PrE0404 
Confidential  
Date: 8/21/2020  
 
55 reaction with eosinophilia and systemic symptoms (DRESS syndrome) 
which should be managed symptomatically according to standard medical 
practice. Punch biopsies for histopathological analysis are encouraged at 
the discretion of the investigator.  
[IP_ADDRESS] Thrombocytopenia  
Blood counts should be monitored regularly as outlined in the protocol with additional testing obtained according to standard clinical pr actice. 
Thrombocytopenia may be severe but has been manageable with platelet transfusions according to standard clinical practice. Ixazomib administration should be modified as noted as per dose modification 
recommendations in the protocol when thrombocytopenia occurs ( Table 
6-3). Therapy can be reinitiated at a reduced level upon recovery of 
platelet counts. A rare risk is thrombotic thrombocytopenic purpura (TTP), 
a rare blood disorder where blood clots form in small blood vessels throughout the body characterized by [CONTACT_12703], petechiae, fever, or possibly more serious signs and symptoms. TTP should be managed 
symptomatically according to standard medical practice.  
[IP_ADDRESS] Neutropenia  
Blood counts should be monitored regularly as outlined in the protocol 
with additional testing obtained according to standard clinical practice.  
Neutropenia may be severe but has been manageable. Growth factor 
support is not required but may be considered according to standard 
clinical practice. Ixazomib administration should be modified as noted as 
per dose modification recommendations in the protocol when neut ropenia 
occurs ( Table 6-3 ). Therapy can be reinitiated at a reduced level upon 
recovery of ANCs.  
[IP_ADDRESS] Fluid Deficit  
Dehydration should be avoided since ixazomib may cause vomiting, diarrhea, and dehydration. Acute renal failure has been reported in patients treated with ixazomib, commonly in the setting of the previously noted gastrointestinal toxicities and dehydration.  
Fluid deficit should be corrected before initiation of study drug and as needed during treatment to avoid dehydration.  
[IP_ADDRESS] Hypotension  
Symptomatic hypotension and orthostatic hypotension with or without syncope hav e been reported with ixazomib. Blood pressure should be 
closely monitored while the patient is on study treatment and fluid deficit 
should be corrected as needed, especially in the setting of concomitant symptoms such as nausea, vomiting, diarrhea, or anorexia.  Patients 
taking medications and/or diuretics to manage their blood pressure (for 
either hypo- or hypertension) should be managed according to standard 
clinical practice, including considerations for dose adjustments of their concomitant medications during the course of the trial.  Fluid deficit should 
be corrected before initiation of study drug and as needed during treatment to avoid dehydration.  
[IP_ADDRESS] Posterior Reversible Encephalopathy Syndrome  
One case of posterior reversible encephalopathy syndrome, which ultimately resolved, has been reported with ixa zomib. This condition is 
characterized by [CONTACT_12704], seizures and visual loss, as well as abr upt 
PrECOG Protocol Number: PrE0404 
Confidential  
Date: 8/21/2020  
 
56 increase in blood pressure.  Diagnosis may be confirmed by [CONTACT_12705] (MRI). If the syndrome is diagnosed or suspected, 
symptom -directed treatment should be maintained until the condition is 
reversed by [CONTACT_12706].  
[IP_ADDRESS]  Transverse Myelitis  
Transverse myelitis has also been reported with ixazomib. It is not known if ixazomib causes transverse myelitis;  however, because it happened to 
a patient receiving ixazomib, the possibility that ixazomib may have contributed to transverse myelitis cannot be excluded.  
11.2 Ibrutinib37 
11.2.1  Other Names  
Additional names for ibrutinib include Imbruvica® and PCI -[ZIP_CODE].  
11.2.2  Classification  
Ibrutinib is an oral inhibitor of Bruton’s tyrosine kinase.  Ibrutinib is approved for the 
treatment of patients with Mantle Cell Lymphoma  and will be obtained 
commercially.  
11.2.3  Mode of Action  
Ibrutinib is a small -molecule inhibitor of BTK. Ibrutinib forms a covalent bond with 
cysteine residue in the BTK active site, leading to inhibition of BTK enzymatic activity.  
BTK is a signaling molecule of the B -cell antigen receptor (BCR) and cytokine receptor 
pathways. BTK’s role in signaling through the B -cell surface receptors results in 
activation of pathways necessary for B- cell traffick ing, chemotaxis, and adhesion. 
Nonclinical studies show that ibrutinib inhibits malignant B- cell proliferation and survival 
in vivo as well as cell migration and substrate adhesion in vitro.  
11.2.4  Storage and Stability  
Ibrutinib is provided as white opaque 140 mg capsules marked with “ibr 140 mg” in 
black ink. Bottles should be stored at room temperature 20 °-25°C (68°- 77°F). 
Excursions are permitted between 15°C and 30°C (59°F to 86°F).  
11.2.5  Dose Specifics  
Ibrutinib shall be obtained through available commercial pharmacies. Patients should take the dose as prescribed by [CONTACT_12707], with a maximum dose of 560 mg (4 tablets). Doses should be t aken at  the same time each day.  Ibrutinib should 
be swallowed whole with water and the tablets should not be opened, broken, or 
chewed.  If a dose of ibrutinib is not taken at the scheduled time, it can be taken as 
soon as possible on the same day with a return to the normal schedule the following 
day. Extra capsules of ibrutinib should not be taken to make up for the missed dose.  
Refer to Section 6.5.2 and Table 6-6 for Dose Delays and Modifications details.  
11.2.6  Route of Administration  
Ibrutinib shall be consumed orally, with the full capsules  swallowed for each dosing.  
Ibrutinib Medication Diary will be reviewed for compliance and collected every cycle for 
Cycle 1 -6 [Appendix IV]. Starting with Cycle 7, Ibrutinib Medication Diar y will be 
reviewed  and collected every 3 cycles.  
11.2.7  Drug Interactions  
Ibrutinib is primarily metabolized by [CONTACT_9058] P450 enzyme  3A. 
PrECOG Protocol Number: PrE0404 
Confidential  
Date: 8/21/2020  
 
57 [IP_ADDRESS]  CYP3A Inhibitors  
Concomitant use of strong CYP3A inhibitors which would be taken 
chronically (e.g., ritonavir, indinavir, nelfinavir, saquinavir, b oceprevir, 
telaprevir, nefazodone) is not recommended. For short -term use 
(treatment for 7 days or less) of strong CYP3A inhibitors (e.g., antifungals 
and antibiotics  such as ketoconazole, itraconazole, voriconazole, 
posaconazole, clarithromycin, telithrom ycin) consider interrupting ibrutinib 
until the CYP3A inhibitor is no longer needed. Reduce ibrutinib to [ADDRESS_12196] be used (e.g., fluconazole, darunavir, erythromycin, diltiazem, atazanavir, aprepi[INVESTIGATOR_053], amprenavir, 
fosamprena vir, crizotinib, imatinib, verapamil, and ciprofloxacin).  
Patients  taking concomitant strong or moderate CYP3A4 inhibitors should 
be monitored more closely for signs of ibrutinib toxicity . 
Avoid grapefruit and  Seville oranges during ibrutinib treatment,  as these 
contain moderate inhibitors of  CYP3A . 
[IP_ADDRESS]  CYP3A Inducers  
Administration of ibrutinib with rifampin, a strong  CYP3A inducer, 
decreased ibrutinib  C max and AUC  by [CONTACT_3450]  13- and 10-fold, 
respectively.  
Avoid  concomitant use of strong CYP3A inducers (e.g.,  carbamazepi[INVESTIGATOR_050], 
rifampin, phenytoin and St. John’s  Wort).  Consider  alternative agents 
with less CYP3A induction . 
11.2.8  Availability  
Ibrutinib shall be obtained through commercial or other sources  and shall not be 
provided by [CONTACT_1758] . 
11.2.9  Side Effects  
There are no listed contra- indications for ibrutinib.  
[IP_ADDRESS]  Hemorrhage 
Fatal bleeding events have occurred in patients treated with ibrutinib . 
Grade 3 or higher bleeding events (subdural hematoma, gastrointestinal 
bleeding, hematuria and post procedural hemorrhage) have occurred in up to 6% of patients. Bleeding events of any grade, including bruising and petechiae, occurred in approximately half of patients treated with ibrutinib . 
The mechanism for the bleeding events is not well understood.  
Ibrutinib  may increase the risk of hemorrhage in patients receiving 
antiplate let or anticoagulant therapi[INVESTIGATOR_014].  
Consider the benefit -risk of withholding ibrutinib  for at least [ADDRESS_12197] -surgery depending upon the type of surgery and the risk of 
bleeding. 
[IP_ADDRESS]  Infections  
Fatal and non- fatal infections have occurred with ibrutinib therapy. Grade 
3 or greater infections occurred in 14% to 26% of  patients. Cases of 
progressive multifocal leukoencephalopathy (PML) have occurred in patients treated with ibrutinib . Monitor patients for fever and infections and 
evaluate promptly.  
PrECOG Protocol Number: PrE0404 
Confidential  
Date: 8/21/2020  
 
58 [IP_ADDRESS]  Cytopenias  
Treatment -emergent Grade 3 or 4 cytopenias including neutropenia 
(range, 19 to 29%), thrombocytopenia (range, 5 to 17%), and anemia 
(range, 0 to 9%) occurred in patients treated with ibrutinib . 
[IP_ADDRESS]  Atrial Fibrillation  
Atrial fibrillation and atrial flutter (range, 6 to 9%) have occurred in patients treated with ibrutinib, particularly in patients with cardiac risk factors, acute 
infections, and a previous history of atrial fibrillation. Periodically monitor patients clinically for atrial fibrillation. Patients who develop arrhythmic symptoms (e.g., palpi[INVESTIGATOR_814], lightheadedness) or new onset dyspnea 
should have an ECG performed. If atrial fibrillation persists, consider the 
risks and benefits of ibrutinib  treatment and dose modification. 
[IP_ADDRESS]  Second Primary Malignancies  
Other malignancies (range, 5 to 14%) including non -skin carcinomas 
(range, 1 to 3%) have occurred in patients treated with ibrutinib . The most 
frequent second primary malignancy was non- melanoma skin cancer 
(range, 4 to 11 %).  
[IP_ADDRESS]  Tumor Lysis Syndrome 
Tumor lysis syndrome has been reported with ibrutinib therapy. Monitor 
patients closely and take appropriate precautions in patients at risk for tumor lysis syndrome (e.g. high tumor burden).  
11.2.10  Nursing/Patient Implications  
Based on findings in animals, ibrutinib can cause fetal harm when administered to a pregnant woman. Ibrutinib caused malformations in rats at exposures 14 times those reported in patients with MCL and 20 times those reported in patients with C hronic 
Lymphocytic Leukemia or Waldenström’s Macroglobulinemia, receiving the ibrutinib 
dose of [ADDRESS_12198] to a fetus.  
Women who are nursing are not eligible for this study and any woman who becomes pregnant over the course of the study will be removed from study therapy.  
Ibrutinib is a Pregnancy Category D drug.  
Please refer to the commercial package i nsert  for full prescribing information. 
PrECOG Protocol Number: PrE0404 
Confidential  
Date: 8/21/2020  
 
59 12. Statistical Considerations 
12.1 Study Design & Sample Size Considerations  
This study will be conducted in two phas es: Phase I and P hase II.  The phase I portion will 
include dose- escalation and de- escalation designed to identify the RP2D/MTD  for the 
combination of ixazomib and ibrutinib for the  phase II portion of the study.  Based on the 
planned dose escalation and de- escalation described below, w e will enroll a minimum of 6 
patients  (assuming DLT on levels 1 & -1) and a maximum of 12 patients (assuming 6 patients 
accrued to two dose levels) on the phase I portion of the study.  
Phase I Summary:  Three patients were enrolled to Dose Level 1 with no DLTs during the 28 
day assessment period. Nine patients were enrolled t o Dose Level 2. Five of the nine  patients 
completed the 28 day assessment period with no DLTs.  One patient experienced a DLT. Three 
of the nine patients  were not evaluable for DLT and were replaced. One patient was 
inadvertently given neulasta prior to receiving Cycle 2, Day 1 therapy;  another patient 
unintentionally took Day 15 ixazomib on Day 9; and one patient forgot to take ibrutinib the last 
8 days of Cycle 1 unrelated to any toxicities . Phase I was completed November 25, 2019.  
Dose Level 2 is the recommended Phase 2 dose.  
12.1.1  Phase I  
For the phase I portion of the study, the primary objective will be to evaluate safety 
and toxicity of ixazomib  when administered in combination with ibrutinib for patients 
with relapsed/refractory MCL, which we will asses s by [CONTACT_12708]/RP2D  as 
described in Section 6.2.1. We will determine this using a standard 3+[ADDRESS_12199] 28-
day cycle, with DLT defined according to Table 6-2. If zero patients experience a DLT, 
the next cohort of 3 will be accrued at the next dose level. If 1 patient experiences a 
DLT, the next cohort of 3 will be accrued at the same dose level to further evaluate safety.  If 2 or 3 patients experience a DLT, that level will be deemed too toxic and  next 
cohort of 3 will  be accrued to Dose Level ( -1). If D ose Level ( -1) proves too toxic, the 
study will end. If [ADDRESS_12200] 3+3 design.  
 True DLT Rate  
1% 5% 10% 15% 20% 30% 40% 50% 
Probability of Dose escalation  .999 .973 .906 .814 .709 .494 .309 .172 
Probability of Dose de- escalation  .001 .027 .094 .186 .291 .506 .691 .828 Dose Level  Ixazomib  
Days 1, 8, 15 of a 
28 Day Cycle  Ibrutinib  
Days 1 -28 of a 
28 Day Cycle  
-1  3 mg  420 mg 
1 
Starting Dose  3 mg  560 mg 
2  4 mg  560 mg 
PrECOG Protocol Number: PrE0404 
Confidential  
Date: 8/21/2020  
 
60 12.1.2  Phase II  
For the phase II portion of the study, we will accrue patients to two cohorts  (BTK- naïve  
[Cohort A]  and BTK- pretreated [Cohort B]) simultaneously.  The primary endpoint for 
the phase II study will be the CR rate, with planned comparison to historical controls. 
The target CR rate for the BTK- naïve cohort will be 40%, based on a historical rate of 
21% for single agent ibrutinib, and the target CR rate for the BTK- pretreated cohort 
will be 23% based on a single agent  CR rate of 8% for bortezomib. As a result, we will 
accrue 31 eligible, treated patients to each cohort for a total of 62 eligible, treated 
patients for the phase II study.  To assure an adequate number of eligible, treated 
patients, up to 36 patients will be enrolled to each arm.  
[IP_ADDRESS]  Administrative Changes: August 7, 2020  
Due to administrative and/or industry sponsor reasons, it was decided that 
enrol lment to Cohort B (BTK -pretreated cohort) will be stopped. The total 
number of BTK -pretreated patients enrolled was [ADDRESS_12201] 7, 2020.  
Enrollment to Cohort A (BTK- naïve cohort) will continue however, and up 
to the full accrual of 36 patients as initially planned. To supplement the enrollment of 36 patients in Cohort A, the BTK -naïve patients that were 
treated at the R2PD in Phase I (n=6) will contribute to the 36 patients 
needed for full accrual in Phase II.  
The statistical operating characteristics, and primary endpoint, of the BTK -
naïve cohort remains the same as indicated in Section 12.1.2 above.  
12.2 Phase II  
12.2.1  Primary Objectives  
Patients will receive oral  ixazomib  and ibrutinib, in combination,  at the RP2D. The 
efficacy of  ixazomib  and ibrutinib therapy will be assessed using CR rate. The CR rate 
will be the defined as the percentage of patients who achiev e a CR (confirmed by [CONTACT_12709]) within the first 12 months of initiating treatment.  Patients who are unevaluable 
or whose CR is not confirmed by [CONTACT_12710]-responders when computing the CR rate.  Relapse/progression will be defined as 
either frank progression by [CONTACT_12711] (i.e., increased circulating 
monoclonal lymphocytes) or progressive disease by [CONTACT_12712], defined according 
to standard criteria.[ADDRESS_12202] 7 , 2020:  BTK- pretreated cohort closed.  
Based on a historical single -agent 21% CR rate of ibrutinib in relapsed/refractory 
MCL
4, we would consider a CR rate of 40% for the combination therapy  in the BTK-
naïve cohort (Cohort A) to be of interest . To detect an improvement of CR rate to 40% 
from the historical CR rate of 21%, a total of [ADDRESS_12203] 86% power and 10% one- sided Type I error using an exact 
binomial test and the null hypothesis will be rejected if CR is observed in 10 or more patients.  
For the BTK- pretreated cohort (Cohort B) a CR rate of 23% will be of interest and a 
CR rate of 8%, based on a previously reported single agent CR rate for bortezomib, will not be of interest. To detect an improvement in CR rate to 23% from 8%, a total of [ADDRESS_12204] 87% power and 
PrECOG Protocol Number: PrE0404 
Confidential  
Date: 8/21/2020  
 
61 10% one- sided Type I error using an exact binomial test and the null hypothesis will 
be rejected if CR is observed in [ADDRESS_12205] 7 , 2020:  BTK- pretreated 
cohort closed.  
12.2.2  Secondary Objectives  
The secondary objectives for phase I and II of this study will include evaluation of 
regimen- related toxicities for the combination of ixazomib and ibrutinib in 
relapsed/refractory MCL; eval uation of the OR R for the drug combination; and to 
evalua te the median PFS and O S for patients treated with the drug combination.  
To describe the ORR  for phase I and II, descriptive statistics will be used to compute 
the proportion of patients who achieved complete and partial response to the drug combination. A 90% exact binomial confidence interval  (CI) around the overall 
response rate estimate from the phase II portion of this study will be computed for 
descriptive purposes. Based on the planned dose escalation and de- escalation, 
between 6 and 1 2 patients will be accrued to the p hase I portion of this study.  
The median PFS and OS will be evaluated using the Kaplan Meier method, separately 
for phase I and II patients. The estimates from the phase I will give preliminary information about efficacy  which w ill be further assessed in the phase II patients. The 
patients included in survival efficacy analysis will include eligible and treated patients 
only.  
All enrolled patients who receive treatment, irrespective of eligibility, will be reviewed for toxicities attributable to treatment. The phase I assessment of treatment -related 
toxicities of Grade 3 or higher  will be described using proportions. In phase II, if  72 
patients (up to 36 in each cohort ; August 7 , 2020:  BTK- pretreated cohort closed. ) 
are treated and assuming there is an equal rate of toxicity in both cohorts, the maximum width of 90%  CI on the proportion of treatment -related grade 3 or higher 
toxicity in both cohorts, combined, will be no wider than 20% . The probability of 
observing at least one rare toxicity (true  rate of 5%) is approximately 97.5%.  August 
7, 2020:  Among 36 treated patients, the maximum 2 -sided width of a 90% CI around 
the proportion of treatment related Grade 3 or higher toxicity will be within 29.4% and the probability of seeing ≥1 rare toxicity if such toxicity has a true prevalence of 5% for example is 84.2%.  
We will also de scribe and tabulate all adverse events, regardless of treatment 
attribution.  
To assure an adequate number of eligible, treated patients, up to 36 patients will be enrolled to each arm. This will result in a maximum accrual of 84 patients for the full 
study  (August 7 , 2020:  BTK- pretreated cohort closed; updated per Section 
[IP_ADDRESS]) . 
The efficacy assessment population will include all eligible and treated patients while 
the adverse events assessment population will include all treated patients, regardless 
of eligibility.  
12.[ADDRESS_12206] of the study.  For the phase I portion of the study, all patients will be evaluated 
for the development of a DLT  as defined in Section 6.2.1. Those patients experiencing 
a DLT shall be removed from study therapy and the dosing for subsequent cohorts of patients shall be adjusted as described in the protocol.  
 
PrECOG Protocol Number: PrE0404 
Confidential  
Date: 8/21/2020  
 
62 All other toxicities or adverse events encountered for all patients from the time of study 
treatment  initiation ( any toxicities or adverse events related to a protocol- mandated 
intervention after  informed consent is signed will also be included)  until the withdrawal 
of consent or the patient has been off study therapy for [ADDRESS_12207] to review the safety of all enrolled patients and ensure compliance w ith all appropriate guidelines.  
12.3.2 Analyses of Correlative Studies  
 
 
 
 
 
 
 
 
 
 
 
 
 

PrECOG Protocol Number: PrE0404 
Confidential  
Date: 8/21/2020  
 
63 13. Laboratory and Pathology  Correlative Studies 
13.1 Correlative S tudies  
13.1.1 Overview  
In addition to the planned primary assessments of safety/tolerability and efficacy of the 
combination, we will also evaluate several candidate predictive and prognostic biomarkers in MCL through analysis of mandatory collected tissue samples, bone 
marrow aspi[INVESTIGATOR_4026], and peripheral blood. In addition, patient samples collected at pre-
specified time points shall be sent to the ECOG -ACRIN Central Biorepository 
Pathology Facility (E -A CBPF)  to be stored and used for future study.  
Several of the planned analyses shall take place at the local site under the supervision of the treating investigators while others shall be conducted centrally through the use of the repository.  
NOTE:  If sufficient bone marrow and tumor tissue are available, submission is 
mandatory. No bone marrow biopsy/aspi[INVESTIGATOR_12670].  
13.1.2 Methodology  
Local Assays:  
Ki67 P roliferative I ndex:  The Ki67 proliferative index shall be assessed for all tumor 
samples used to confirm the diagnosis of relapsed MCL f or the purposes of this study. 
This shall be conducted according to each institutional practice and shall be reported 
as a percentage of cells expressing Ki67. This shall occur at one time poi nt at the time 
of study entry. Patients for whom there is no tissue available to conduct this asses sment will NOT  require repeat biopsies simply for the purposes of conducting 
this assessment.  
Cytogenetic A nalyses:  Each site shall submit a bone marrow aspi[INVESTIGATOR_12671]/or 
a tumor tissue sample (nodal or extranodal) for cytogenetic assessments. These 
assessments shall be conducted locally according to institutional standards.  In 
addition to a conventional cytogenetic assessment, samples shall be assessed by 
[CONTACT_4656] f or t(11;14) and FISH for del(17p).  Patients shall require 1 (one) sample (either 
from the bone marrow or from involved tissue) with preference given towards using a 
sample that is known to be involved with MCL. 
Vitamin D Level A ssessment:  All patients at the time of study enrollment will have a 
25(OH) Vitamin D3 level drawn by [CONTACT_12713]. This one- time assessment 
will be processed locally . 
Centrally Processed Assays:  
Peripheral blood and involved tissue samples shall be sent to a central lab  for future 
use. Planned assessments include the following:  
PSMB1 Allele F requency:  Given the potential association of the PSMB1 P11A (G 
allele) with prolonged PFS and OS in patients treated with bortezomib, we will assess the allelic frequency among enrolled patients.  All patients will prov ide a peripheral 
blood sample at the time of enrollment tha t will be utilized to evaluate allelic frequency. 
This shall be determined using a TaqMan SNP assay.  
BTK Mutational A nalysis:  All patients will have a mutational analysis of BTK and 
PLC-γ2 perfor med on involved tissue samples.  This will be performed using the 
commercially available NeoGenomics assay and will require Formalin -Fixed, Paraffin-
Embedded ( FFPE ) tissue or bone marrow from aspi[INVESTIGATOR_337].  
Future studies: We will collect and store  samples for future correlative studies  and 
will be incorporated into this protocol as future amendments as they are developed.  
PrECOG Protocol Number: PrE0404 
Confidential  
Date: 8/21/2020  
 
64 13.1.3  Sample Collection  
Kits will be supplied  for research samples. Instructions will be provided in the kit.  
Planned research assessments and required submissions : 
Screening/Study Entry  
Local, per Institutional Practice  
• Ki67 assessment  
• Conve ntional cytogenetics  
• FISH for t(11;14)  
• FISH for del(17p)  
• 25(OH) Vitamin D  
Research Samples  
• Peripheral Blood: Two 6  mL in EDTA tubes  
• BM aspi[INVESTIGATOR_337]: 10 mL in EDTA tube  
• Formalin -Fixed, Paraffin-E mbedded ( FFPE ) tissue (block preferred or 1 H&E slide 
plus 10 unstained slides)  
After Cycle 3  
Up to 5 days before Cycle 4, Day 1  
Peripheral Blood: Two  6 mL in EDTA tubes  
Suspected CR  
At Time of Suspected CR  
Peripheral Blood: Two 6  mL in EDTA tubes  
End of Therapy/At Time of P rogression  
Within [ADDRESS_12208] dose of study medication  
• Peripheral Blood: Tw o 6 mL in EDTA tubes  
NOTE:  If sufficient bone marrow and tumor tissue are available, submission is 
mandatory. No bone marrow biopsy/aspi[INVESTIGATOR_12672].  
13.1.4  Research Samples Processing and Shipment  
Instructio ns, shippi[INVESTIGATOR_12673], supplies and address will be provided in the kits . 
All samples collected will be labeled with a unique numeric identifier that will be coded for patient privacy protection.  
[IP_ADDRESS]  FFPE Tissue Block or Slide Samples  
Sites should submit FFPE tumor tissue blocks or  FFPE slides (2 sections 
per slide) plus H&E slide from a tumor tissue block as noted in Section 
13.1.3. Thickness of the sections should be at 4- 5 micron. 
Screening/Study Entry samples should be submitted within 1 month of 
patient registration.  
A copy of the pathology report  should be sent when the sample is shipped. 
Samples should be shipped Monday -Thursday . Samples will be shipped 
ambient via overnight courier.  
PrECOG Protocol Number: PrE0404 
Confidential  
Date: 8/21/2020  
 
65 [IP_ADDRESS]  Bone Marrow (BM) Samples  
Sites should submit BM samples in EDTA tubes as noted in Section 
13.1.3.  
Store  in the freezer at ≤ -70°C or colder until  shipped to central  lab. 
BM samples should be submitted within [ADDRESS_12209] 
be shipped on dry ice via overnight courier.  
[IP_ADDRESS]  Peripheral Blood Samples  
Sites should submit peripheral blood samples in EDTA tubes as noted in 
Section 13.1.3.  
EDTA Tube Processing for Plasma and Buffy Coat  
**Process sample within 30 minutes of  collection**  
• Gently mix blood sample by [CONTACT_8536] 10 times (do not shake).  
• Place tube immediately on wet ice for 5 minutes.  
• Centrifuge at 1200 RPM for 15 minutes at 4° C. If a refrigerated 
centrifuge is not available, spin sample at room temperature (1200 
RPM for 15 minutes). Immediately place the tube on wet ice after centrifugation.  
After centrifugation, the plasma layer will be at the top half of the tube. 
The nucleated cells (WBC) will be in a whitish layer, called the “buffy coat”, 
just under the plasma and above the red blood cells.  
Plasma  Preparation : 
• Using a transfer pi[INVESTIGATOR_12674]- thirds of the plasma and 
transfer plasma into a 15 ml conical centrifuge tube, be careful not to disturb the buffy coat layer in the EDTA tube ( NOTE:  see below for 
buffy coat processing instructions). Centrifuge the 15 ml conical tube 
at 1200 RPM for 15 minutes at 4° C. If a refrigerated centrifuge is not 
available, spin sample at room temperature (1200 RPM for 15 minutes). Immediately place the conical tube on wet ice after 
centrifugation.  
• Transfer equal amounts of plasma into two (2) properly labeled 
polypropylene tubes for cryopreservation being careful not to disturb 
the small PBMC/pellet . 
• Store the two aliquots of plasma samples in the freezer at ≤ -70°C or 
colder until they are shipped to central lab. 
Buffy Coat  Preparation: 
• From the EDTA tube remove and aliquot the “buffy coat”; be careful 
not to disturb the layer of  red blood cells.  
• Store the  aliquot of cells in two (2) properly labeled polypropylene 
tube for cryopreservation.  
• Store the sample in the freezer at ≤ -7 0°C or colder until it is sh ipped 
to central lab. 
PrECOG Protocol Number: PrE0404 
Confidential  
Date: 8/21/[ADDRESS_12210] be shipped on dry 
ice via overnight courier . 
PrECOG Protocol Number: PrE0404 
Confidential  
Date: 8/21/[ADDRESS_12211] 
be discussed with, and be prepared by [CONTACT_12714]/or representatives. The Investigator should not implement any deviation or change to the protocol or consent without prior review and documented approval from PrECOG and/or representatives and the Institutional Review 
Board ( IRB) of an amendment, except where necessary to eliminate an immediate hazard(s) 
to study patients.  
If a deviation or change to the approved protocol is implemented to eliminate an immediate hazard(s) prior to obtaining IRB approval, notification will be submitted to the IRB for review and approval as soon as possible afterward. Documentation of approval signed by [CONTACT_12715](s) should be in the study records. If PrECOG and/or representatives provides an amendment that substantially alters the study design or increases the potential risk to the patient; the consent form must be revised and submitted to the IRB(s) 
for review and approval; the revised form must be used to obtain consent from patients 
currently enrolled in the study if they are affected by [CONTACT_12716]; and the new form must be used to obtain consent from new patients prior to study entry. Information as to  who 
investigators should send correspondence will be provided in additional study documents.  
14.[ADDRESS_12212]  (IRB)  
Before study initiation, the Investigator must have written and dated approval from their respective IRB for the protocol, consent form, patient recruitment materials/process and any other written information to be provided to patients. The Investigator should also provide the IRB with a copy of the Investigator Brochure or product labeling, and any updates.  
The Investigator should provide the IRB with reports, updates, and other information (e.g., Safety Updates, amendments, and administrative letters) according to regulatory 
requirements, IRB or study site procedures.  
14.[ADDRESS_12213] ensure that  patients who volunteer for clinical trials or their legally 
acceptable representative are clearly and fully informed about the purpose, potential risks and 
other information.  
A protocol specific informed consent form (ICF) template will be provided to sit es. Preparation 
of the site- specific consent form is the responsibility of the site Investigator and must include 
all applicable regulatory and IRB requirements, and must adhere to Good Clinical Practices (GCP) and to the ethical principles that have their  origin in the Declaration of Helsinki. All 
changes to the ICF template will be approved by [CONTACT_12714]/or their representatives prior to implementation.  
In accordance with the Health Information Portability and Accountability Act (HIPAA), the 
consent process will also include written authorization by [CONTACT_12717]/or its agents, regulatory authorities, and the IRB of record at the study site for access to patient records and medical information relevant to the s tudy, 
including the medical history. This will be documented in the informed consent form or other approved form obtained at the time of informed consent per institutional policies. This form 
should also be submitted to PrECOG and/or its agents for review prior to its implementation.  
The Investigator must provide the patient or legally acceptable representative with a copy of 
the consent form and written information about the study in the language in which the patient is most proficient. The language must be non- technical and easily understood. The Investigator 
should allow time necessary for patient or patient's legally acceptable representative to inquire about the details of the study, then informed consent must be signed and personally dated by 
[CONTACT_12718]'s legally acceptable representative and by [CONTACT_12719]: PrE0404 
Confidential  
Date: 8/21/2020  
 
68 the informed consent discussion. The patient or legally acceptable representative should 
receive a copy of the signed informed consent and any other written information provided to study patients prior to patient's participation in the trial. The investigator is responsible for assuring adequate documentation of this process and for storage and maintenance of the original signed consent form for each patient/subject.  
The informed consent and any other information provided to patients or the patient's legally 
acceptable representative, should be revised whenever important new information becomes available that is relevant to the patient's consent, and should receive IRB approval prior to use. The Investigator, or a person designated by [CONTACT_12720]'s legally acceptable representative of all pertinent aspects of the study and of any new 
information relevant to the patient's willingness to continue participation in the study. This 
communication should be documented in the patient record. During a patient's participation in the trial, any updates to the consent form and any updates to the written information will be provided to the patient.  
14.[ADDRESS_12214] review and retain the notice with the Investigator Brochure and submit a copy of this information to the IRB according to local regulations. The Investigator and IRB will determine 
if the informed consent requires revision. The Investigator should also comply with the IRB procedures  for reporting any other safety information. All revisions should be submitted to 
PrECOG and/or agents for review.  
14.[ADDRESS_12215] be 
allowed access to electronic Case Report Forms ( eCRFs ), source documents and other study 
files. The Investigator must notify PrECOG of any scheduled visits by [CONTACT_12721], and submit copi[INVESTIGATOR_12675]. Information as to who investigators should notify of an audit 
or where to address questions will be provided i n additional study materials.  
14.[ADDRESS_12216] be protected, respecting the privacy and confidentiality rules in accordance with the applicable regulatory requirement(s).  
A study specific signature [CONTACT_12729] a study site who are authorized to make entries and/or corrections on eCRFs as well as document other study -specific roles.  
 
PrECOG Protocol Number: PrE0404 
Confidential  
Date: 8/21/2020  
 
69 14.7 Electronic Case Report Form (eCRF) Information  
Additional information regarding eCRF instructions, timelines for data entry/ submission and 
query completion can be found in supplemental materials provided to the site. Sites will be 
expected to complete eCRFs as per the schedule provided and submit all relevant data as per the specified timelines. All items recorded on eCRFs must be found in source documents.  
The completed eCRF must be promptly reviewed, electronically signed, and dated by [CONTACT_079].  
Instructions for management of patients who do not receive any protocol therapy:  
If a patient is registered and does not receive any assigned protocol treatment, baseline, 
Serious Adverse Event and follow -up data will still be entered and must be submitted according 
to the eCRF instructions. Document the reason for not starting protocol treatment on the appropriate electronic off treatment form.  
14.8 Records Retention  
FDA Regulations (21CFR 312.62) require clinical investigators to retain all trial -related 
documentation, including source documents for the periods described below for studies performed under a US Investigational New Drug ( IND): 
• two years after the FDA approves the marketing application, or  
• two years after the FDA disapproves the application for the indication being studied, or  
• two years after the FDA is notified by [CONTACT_12722].  
The Investigator must retain investigational product disposition records, copi[INVESTIGATOR_1495] (or 
electronic files), and source documents for the maximum period required by [CONTACT_12723], or Institution procedures, whichever is longer. The Investigator must contact [CONTACT_12714]/or representatives prior to destroying any records associated with the study.  
Information as to who investigators should contact [CONTACT_12724]. PrECOG and/or representatives will notify the Investigator when the trial 
records for this study are no longer needed.  
 
PrECOG Protocol Number: PrE0404 
Confidential  
Date: 8/21/2020  
 
70 15. References  
1. Nastoupil LJ, Shenoy PJ, Ambinder A, et al: Intensive chemotherapy and consolidation with high 
dose therapy and autologous stem cell transplant in patients with mantle cell lymphoma. Leuk 
Lymphoma:1- 20, 2014. 
2. Delarue R, Haioun C, Ribrag V, et al: CHOP and DHAP plus rituximab followed by [CONTACT_12725]: a phase 2 study from the Groupe d'Etude des 
Lymphomes de l'Adulte. Blood 121:48- 53, 2013. 
3. Damon LE, Johnson JL, Niedzwiecki D, et al: Immunochemotherapy and autologous stem -cell 
transplantation for untreated patients with mantle- cell lymphoma: CALGB [ZIP_CODE]. J Clin Oncol 
27:6101- 8, 200 9. 
4. Wang ML, Rule S, Martin P, et al: Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma. N Engl J Med, 2013. 
5. Goy A, Sinha R, Williams ME, et al: Single- Agent Lenalidomide in Patients With Mantle- Cell 
Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib: Phase II MCL-
001 (EMERGE) Study. J Clin Oncol 31:3688- 95, 2013. 
6. Fisher RI, Bernstein SH, Kahl BS, et al: Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 24:4867- 74, 2006. 
7. Wang ML, Blum KA, Martin P, et al: Long- term follow -up of MCL patients treated with single-
agent ibrutinib: Updated safety and efficacy results. Blood, 2015 . 
8. Cheah CY, Chihara D, Romaguera JE, et al: Patients with mantle cell lymphoma failing ibrutinib 
are unlikely to respond to salvage chemotherapy and have poor outcomes. Ann Oncol 26:1175-9, 2015. 
9. Kaplan LD, Jung S -H, Stock W, et al. Bortezomib maintenance versus consolidation following 
aggressive immunochemotherapy and autologous stem cell  transplant for untreated mantle cell lymphoma: CALGB (Alliance) [ZIP_CODE]. Blood 2015, 126: 337. 
10. Chang JE, Li H, Smith MR, et al: Phase II study of VcR -CVAD with maintenance rituximab for 
untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group Study (E1405). Blood, 2014 . 
11. William BM, Allen MS, Loberiza FR, Jr., et al: Phase I/II Study of Bortezomib- BEAM and 
Autologous Hematopoietic Stem Cell Transplantation for Relapsed Indolent Non- Hodgkin 
Lymphoma, Transformed, or Mantle Cell Lymphoma. Biol Blood Marrow Transplant, 2014. 
12. Axelrod M, Ou Z, Brett LK, et al: Combinatorial drug screening identifies synergistic co- targeting 
of Bruton's tyrosine kinase and the proteasome in mantle cell lymphoma. Leukemia 28:407- 10, 
2014 . 
13. Kupperman E, Lee EC, Cao Y, et al: Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. Cancer Res 70:1970- 80, 2010. 
14. Lee EC, Fitzgerald M, Bannerman B, et al: Antitumor activity of the investigational pr oteasome 
inhibitor MLN9708 in mouse models of B- cell and plasma cell malignancies. Clin Cancer Res 
17:7313- 23, 2011 . 
15. Martin P, Chang J, Cheson BD, et al: Weekly MLN9708, an Investigational Proteasome Inhibitor, in Patients with Relapsed/Refractory Lymphoma: Phase 1 Dose- Escalation Study. 
Hematological Oncology 31 (Suppl. 1):151- 200, 2013. 
16. Kumar S, Bensinger WI, Zimmerman TM, et al: Weekly MLN9708, an investigational oral proteasome inhibitor (PI), in relapsed/refractory multiple myeloma (MM): Results from a phase I study after full enrollment. J Clin Oncol 31:8514, 2013. 
PrECOG Protocol Number: PrE0404 
Confidential  
Date: 8/21/2020  
 
71 17. Lonial S, Baz RC, Wang M, et al: Phase I study of twice -weekly dosing of the investigational oral 
proteasome inhibitor MLN9708 in patients (pts) with relapsed and/or refractory multiple myeloma 
(MM). Journal of Clinical Oncology 30, 2012. 
18. Kumar SK, Berdeja JG, Niesvizky R, et al: A Phase 1/2 Study of Weekly MLN9708, an Investigational Oral Proteasome Inhibitor, in Combination with Lenalidomide and 
Dexamethasone in Patients wit h Previously Untreated Multiple Myeloma (MM). Blood 120, 2012. 
19. Gupta, N., et al., Clinical Pharmacokinetics of Intravenous and Oral MLN9708, An Investigational 
Proteasome Inhibitor: An Analysis of Data From Four Phase 1 Monotherapy Studies. in 52
nd ASH 
Annual Meeting and Exposition, 2010. 116(21): p. abstr 1813.  
20. Chow, L.Q., et al. MLN9708, an investigational proteasome inhibitor, in patients with solid 
tumors; Updated phase 1 results in Head and Neck Symposium. 2012. Phoenix, AZ . 
21. Assouline, S., et al. Once- weekly MLN9708, an investigational proteasome inhibitor, in patients 
with relapsed/refractory lymphoma: results of a phase 1 dose- escalation study in 17th EHA 
Annual Congress. 2012. Amsterdam, the Netherlands.  
22. Lonial, S., et al. Phase I study of twice- weekly dosing of the investigational oral proteasome 
inhibitor MLN9708 in patients (pts) with relapsed and/or refractory multiple myeloma (MM) in ASCO Annual Meeting. 2012. Chicago, Illinois.  
23. Kumar S, et al. Weekly Dosing of the Investigational Oral Proteasome Inhibitor MLN9708 in 
Patients with Relapsed and/or Refractory Multiple Myeloma: Results From a Phase [ADDRESS_12217] ASH Annual Meeting and Exposition; 2011 10- 13 Dec; San Diego, CA; 
p. abstr 816.  
24. Merlini, G., et al. MLN9708, a Novel, Investigational Oral Proteasome Inhibitor, in Patients with 
Relapsed or Refractory Light -Chain Amyloidosis (AL): Results of a Phase 1 Study in 54th ASH 
Annual Meeting and Exposition. 2012. Atlanta, Georgia.  
25. Kumar, S. et al. A Ph ase 1/2 Study of Weekly MLN9708, an Investigational Oral Proteasome 
Inhibitor, in Combination with Lenalidomide and Dexamethasone in Patients with Previously 
Untreated Multiple Myeloma (MM) in 54th ASH Annual Meeting and Exposition. 2012. Atlanta, 
Georgia.  
26. Richardson, P.G., et al. MLN9708, an investigational proteasome inhibitor, in combination with 
lenalidomide and dexamethasone in previously untreated multiple myeloma patients (pts): Evaluation of weekly and twice- weekly dosing in 17
th EHA Annual Congress. 2012. Amsterdam, 
the Netherlands.  
27. San Miguel, J., et al. Oral MLN9708, an an investigational proteasome inhibitor, in combination 
with melphalan and prednisone in patients with previously untreated multiple myeloma: a phase 
1 study in 17th EHA An nual Congress. 2012. Amsterdam, the Netherlands.  
28. Assouline , S.E.,  et al. Phase 1 dose- escalation study of IV ixazomib, an investigational 
proteasome inhibitor, in patients with relapsed/refractory lymphoma. Blood Cancer Journal (2014) 4, e251; doi:10.1038/bcj.2014.71; published online 17 October 2014.  
29. Maddocks K, Christian B, Jaglowski S, et al: A phase 1/1b study of rituximab, bendamustine, 
and ibrutinib in patients with untreated and relapsed/refractory non- Hodgkin lymphoma. Blood 
125:242- 8, 2015. 
30. Wang M, Hagemeister F, Westin JR, et al: Ibrutinib and Rituximab Are an Efficacious and Safe 
Combination in Relapsed Mantle Cell Lymphoma: Preliminary Results from a Phase II Clinical 
Trial. Blood 124, 2014 . 
31. Woyach JA, Furman RR, Liu TM, et al: Resistance mechanisms for the Bruton's tyrosine kinase 
inhibitor ibrutinib. N Engl J Med 370:2286- 94, 2014. 
PrECOG Protocol Number: PrE0404 
Confidential  
Date: 8/21/2020  
 
72 32. Dasmahapatra G, Patel H, Dent P, et al: The Bruton tyrosine kinase (BTK) inhibitor PCI -[ZIP_CODE] 
synergistically increases proteasome inhibitor activity in diffuse large- B cell lymphoma (DLBCL) 
and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib. Br J Haematol 
161:43- 56, 2013. 
33. Cheson BD, Pfistner B, Juweid ME, et al: Revised response criteria for malignant lymphoma. J 
Clin Oncol 25:579- 86, 2007 . 
34. Kumar S, Bensinger W, Reeder C, Zimmerman T, Berenson J, Liu G, et al. Weekly dosing of the 
investigational oral proteasome inhibitor MLN9708 in patients (pts) with relapsed/refractory multiple myeloma (MM): A phase I study. Journal of Clinical Oncology 2012 ASCO Annual Meeting Proceedings 2012:  Abstract 8034.  
35. Barrington SF, Mikhaeel NG, et al: Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol 32:3028- 3058, 2014.  
36. Millennium Ph armaceuticals, Inc. Ixazomib (MLN9708) Investigator's Brochure, Edition 9; Issue 
Date: [ADDRESS_12218] 2015.  
37. IMBRUVICA
TM (ibrutinib), Prescribing Information; Initial US Approval 2013; revised June 2016. 
PrECOG Protocol Number: PrE0404 
Confidential  
Date: 8/21/2020  
 
73 Appendix I  ECOG Performance Status  
 
PS 0  Fully active, able to carry on all pre- disease performance 
without restriction  
PS 1  Restricted in physically strenuous activity but ambulatory 
and able to carry out work of a light or sedentary nature e.g. 
light house work, office work.  
PS 2  Ambulatory and capable of all self -care but unable to carry 
out any work activities. Up and about more than 50% of 
waking hours.  
PS 3  Capable of only limited self -care, confined to bed or chair 
more than 50% of waking hours.  
PS 4  Completely disabled. Cannot carry on any self -care. Totally 
confined to bed or chair.  
Source: East ern Cooperative Oncology Group, Robert Comis M.D., Group Chair  
PrECOG Protocol Number: PrE0404 
Confidential  
Date: 8/21/2020  
 
74 Appendix II:  NYHA Classification  
 
Class Symptoms 
Class I  Patients with cardiac disease but without resulting limitation of 
physical activity. Ordinary physical activity does not cause 
undue fatigue, palpi[INVESTIGATOR_332], dyspnea (shortness of breath), or 
anginal pain.  
Class II  Patients with cardiac disease resulting in slight limitation of 
physical activity. Comfortable at rest. Ordinary physical activity 
results in fatigue, palpi[INVESTIGATOR_332], dyspnea or anginal pain.  
Class III  Patients with cardiac disease resulting in marked limitation of 
physical activity. Comfortable at rest. Less than ordinary 
physical activity causes fatigue, palpi[INVESTIGATOR_332], dyspnea or anginal pain.  
Class IV  Patients with cardiac disease resulting in inability to carry out any physical activity without discomfort. Symptoms of cardiac insufficiency or the anginal syndrome may be present even at 
rest. If any 
physical activity is undertaken, discomfort is 
increased.  
Oxford Textbook of Internal Medicine. Vol. 2, pp 2228. Oxford University Press. 1997  
 
PrECOG Protocol Number: PrE0404 
Confidential  
Date: 8/21/2020  
 
75 Appendix III:  Ixazomib Medication Diary  
 
Site #:___________  Subject #:___________  Subject Initials:____________  
Cycle:___________ Dose:_______________  Number of Capsule s: ___ mg: ________  
 
Patient Instructions:  
1. Complete each form as instructed by [CONTACT_12726].  Please complete in ink.  
2. Please complete this diary every day  you take ixazomib. Write the date of each dose of ixazomib you 
take.  
3. Ixazomib  should be swallowed whole with a glass of water. Capsule  should not be opened, broken or 
chewed.  Ixazomib  should be taken on an empty stomach (no food or drink) at least [ADDRESS_12219]  (beginning with Cycle 2) . 
5. Extra  capsules should not  be taken  to make up for the missed  dose.  If you vomit  after taking a dose, 
do not repeat the dose but resume dosing at the time of the next scheduled dose . Pleas e mark dates 
of any missed capsule on your record.  
6. Store your medication refrigerated ( 36°F to 46°F) for the duration of each cycle.  
7. If you have any side effects or comments, please note in the comment section or on the back of the 
page. If you have questions or concerns, please call ______________________________________ 
at: (_____) _____ - _________.  
Please brin g your  ixazomib  blister packs (unused medication and empty blister packs) and this 
form to every appointment with your study doctor.  
 
DAY  DATE  DOSE  COMMENTS  
1 ____/____/____  ______mg  
8 ____/____/____  ______mg  
15 ____/____/____  ______mg  
PrECOG Protocol Number: PrE0404 
Confidential  
Date: 8/21/2020  
 
76 Appendix IV: Ibrutinib  Medication  Diary  
 
Site #:___________  Subject #:___________  Subject Initials:____________  
Cycle:___________ Dose:_______________  Number of Capsule s: 140 mg: ________  
 
Patient Instructions:  
1. Complete each form as instructed by [CONTACT_12726]. Please complete in ink.  
2. Please complete this diary every day. Write the date  of each dose of ibrutinib  you take.  
3. Ibrutinib  should be swallowed whole with a glass of water. Capsules  should not be opened, broken or 
chewed.  You should take the capsules at approximately the same time each day.  
4. If a dose is not taken at the scheduled time,  it can be taken as soon as  possible on the same day with 
a return to the normal  schedule the following  day. 
5. Extra  capsules should not  be taken  to make up for the missed  dose.  If you vomit after taking a dose, 
do not repeat the dose but resume dosing at the time of the next scheduled dose. Please mark dates 
of any missed capsule on your record.  
6. You should not drink grapefruit juice,  eat grapefruit, or eat  Seville  oranges (often used in marmalades)  
while you are taking ibrutinib.  These products may increase the amount of  ibrutinib in your  blood.  
7. Store ibrutinib at room temperature 68°- 77°F.  
8. If you have any side effects or comments, please note in the comment section or on the back of the page. If you have questions or concerns, please call ______________________________________ 
at: (_____) _____ - _________.  
Please bring your ibrutinib bottle(s) (unused medication and  empty bottles) and this form to every 
appointment with your study doctor.  
 
DAY  DATE  DOSE  COMMENTS  
1 ____/____/____  ______mg  
2 ____/____/____  ______mg  
3 ____/____/____  ______mg  
4 ____/____/____  ______mg  
5 ____/____/____  ______mg  
6 ____/____/____  ______mg  
7 ____/____/____  ______mg  
8 ____/____/____  ______mg  
9 ____/____/____  ______mg  
10 ____/____/____  ______mg  
11 ____/____/____  ______mg  
PrECOG Protocol Number: PrE0404 
Confidential  
Date: 8/21/2020  
 
77 12 ____/____/____  ______mg  
13 ____/____/____  ______mg  
14 ____/____/____  ______mg  
15 ____/____/____  ______mg  
16 ____/____/____  ______mg  
17 ____/____/____  ______mg  
18 ____/____/____  ______mg  
19 ____/____/____  ______mg  
20 ____/____/____  ______mg  
21 ____/____/____  ______mg  
22 ____/____/____  ______mg  
23 ____/____/____  ______mg  
24 ____/____/____  ______mg  
25 ____/____/____  ______mg  
26 ____/____/____  ______mg  
27 ____/____/____  ______mg  
28 ____/____/____  ______mg  
 
PrECOG Protocol Number: PrE0404 
Confidential  
Date: 8/21/2020  
 
78 Appendix V:  Investigator’s Statement  
1. I have carefully read this protocol entitled  “A Phase I/II Study of Ixazomib and 
Ibrutinib in Patient s with Relapsed/Refractory Mantle Cell Lymphoma”, Version 
3.0 dated 8/21/2020  (Protocol Number PrE0404)  and agree that it contains all the 
necessary information required to conduct the study. I agree to conduct the study as 
outlined in the protocol.  
2. I agree to conduct this study according to the moral, ethical and scientific principles governing clinical  research as set out in the Declaration of Helsinki, the principles of 
Good Clinical Practice (GCP ) as described in 21 Code of Federal Regulations ( CFR) 
and any applicable local requirements. 
3. I understand that this trial and any subsequent changes to the trial will not be initiated 
without approval of the appropriate Institutional Review Board, and that all administrative requirements of the governing body of the institution will be complied 
with fully.  
4. Informed written consent will be obtained from all participating patients in accordance 
with institutional and Food and Drug Administration (FDA)  requirements as specified in 
Title 21, CFR , Part 50.  
5. I understand that my signature [CONTACT_12730]  (eCRF)  indicates 
that I have carefully reviewed each page and accept full responsibility for the contents thereof.  
6. I understand that the information presented in this study protocol is confidential, and I 
hereby [CONTACT_12727], LLC unless this requirement is superseded by [CONTACT_1556]. 
Principal Investigator  (PI): 
PI [CONTACT_5627]:            
Site Name:            
[INVESTIGATOR_377]:           
[CONTACT_1217]:    \  \    
    MM  DD  YYYY  
 
 
 